0001096906-24-000484.txt : 20240318 0001096906-24-000484.hdr.sgml : 20240318 20240318155752 ACCESSION NUMBER: 0001096906-24-000484 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Yo-Health Inc. CENTRAL INDEX KEY: 0001844793 STANDARD INDUSTRIAL CLASSIFICATION: ICE CREAM & FROZEN DESSERTS [2024] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 853135038 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56521 FILM NUMBER: 24758878 BUSINESS ADDRESS: STREET 1: 7551 SHELBY STREET STREET 2: 3RD FLOOR CITY: INDIANAPOLIS STATE: IN ZIP: 46227 BUSINESS PHONE: 5136494881 MAIL ADDRESS: STREET 1: 7551 SHELBY STREET STREET 2: 3RD FLOOR CITY: INDIANAPOLIS STATE: IN ZIP: 46227 10-Q 1 yohe-20230930.htm YO-HEALTH, INC. - FORM 10-Q SEC FILING YO-HEALTH, INC. - Form 10-Q SEC filing
0001844793 --12-31 false 2023 Q3 0001844793 2023-01-01 2023-09-30 0001844793 2023-09-30 0001844793 2024-03-18 0001844793 2022-12-31 0001844793 2023-07-01 2023-09-30 0001844793 2022-07-01 2022-09-30 0001844793 2022-01-01 2022-09-30 0001844793 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 2021-12-31 0001844793 us-gaap:CommonStockMember 2021-12-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001844793 us-gaap:RetainedEarningsMember 2021-12-31 0001844793 2022-01-01 2022-03-31 0001844793 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001844793 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001844793 2022-03-31 0001844793 us-gaap:CommonStockMember 2022-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001844793 us-gaap:RetainedEarningsMember 2022-03-31 0001844793 2022-04-01 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001844793 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001844793 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001844793 us-gaap:RetainedEarningsMember 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001844793 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001844793 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001844793 us-gaap:RetainedEarningsMember 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-12-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001844793 us-gaap:RetainedEarningsMember 2022-12-31 0001844793 2023-01-01 2023-03-31 0001844793 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001844793 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001844793 2023-03-31 0001844793 us-gaap:CommonStockMember 2023-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001844793 us-gaap:RetainedEarningsMember 2023-03-31 0001844793 2023-04-01 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001844793 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001844793 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001844793 us-gaap:RetainedEarningsMember 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001844793 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001844793 us-gaap:CommonStockMember 2023-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001844793 us-gaap:RetainedEarningsMember 2023-09-30 0001844793 2022-01-01 2022-12-31 0001844793 2021-01-01 2021-12-31 0001844793 us-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MinimumMemberus-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MaximumMemberus-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MinimumMemberus-gaap:MachineryAndEquipmentMember 2023-09-30 0001844793 srt:MaximumMemberus-gaap:MachineryAndEquipmentMember 2023-09-30 0001844793 us-gaap:BuildingMember 2023-09-30 0001844793 us-gaap:ComputerEquipmentMember 2022-12-31 0001844793 us-gaap:LandMember 2023-09-30 0001844793 us-gaap:LandMember 2022-12-31 0001844793 fil:CnbBankOhStoreMember 2023-09-30 0001844793 fil:OldNationalBankLaStoreFacMember 2023-09-30 0001844793 fil:OldNationalLoanInFactoryMember 2023-09-30 0001844793 fil:OldNational7kFarmsFactoryMember 2023-09-30 0001844793 fil:CnbBankOhStoreMember 2023-01-01 2023-09-30 0001844793 fil:OldNationalLoanInFactoryMember 2023-01-01 2023-09-30 0001844793 fil:OldNationalBankLaStoreFacMember 2023-01-01 2023-09-30 0001844793 fil:N7kFarmsReOldNationalMember 2023-01-01 2023-09-30 0001844793 fil:PeterAndVilaThawnghmungMemberus-gaap:CommonStockMember 2021-01-01 2021-12-31 0001844793 fil:PeterAndVilaThawnghmungMember 2021-01-01 2021-12-31 0001844793 fil:OtherRelatedPartiesMemberus-gaap:CommonStockMember 2021-01-01 2021-12-31 0001844793 fil:OtherRelatedPartiesMember 2021-01-01 2021-12-31 0001844793 fil:PeterAndVilaThawnghmungMemberus-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:PeterAndVilaThawnghmungMember 2022-01-01 2022-09-30 0001844793 fil:AriannaPhrakornkhamMemberus-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:AriannaPhrakornkhamMember 2022-01-01 2022-09-30 0001844793 fil:OtherRelatedPartiesMemberus-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:OtherRelatedPartiesMember 2022-01-01 2022-09-30 0001844793 fil:PeterAndVilaThawnghmungMemberus-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 fil:PeterAndVilaThawnghmungMember 2023-01-01 2023-09-30 0001844793 fil:RomeThalopMemberus-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 fil:RomeThalopMember 2023-01-01 2023-09-30 0001844793 fil:FlushingNewYorkMember 2023-01-01 2023-09-30 0001844793 fil:ColumbusOhioMember 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana1Member 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana2Member 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana3Member 2023-01-01 2023-09-30 0001844793 fil:ColumbusOhio2Member 2023-01-01 2023-09-30 0001844793 fil:StockIssuance1Memberus-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:StockIssuance1Member 2022-01-01 2022-09-30 0001844793 fil:StockIssuance2Memberus-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:StockIssuance2Member 2022-01-01 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-01-01 2022-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended:  September 30, 2023

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to _________

 

Commission File Number:  333-222631

 

YO-HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

85-3135038

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

7551 Shelby Street, 3rd FL, Indianapolis, IN

 

46227

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (614327-7630

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

None

 

N/A

 

N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 

 

As of March 18, 2024 the registrant had 77,717,721 shares of its common stock issued and outstanding.


 

YO-HEALTH, INC.

 

QUARTERLY REPORT ON FORM 10-Q

 

September 30, 2023

 

TABLE OF CONTENTS

 

 

PAGE

PART I - FINANCIAL INFORMATION

1

 

 

Item 1.

Condensed Consolidated Financial Statements

1

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

20

 

 

 

Item 4.

Controls and Procedures

20

 

 

 

PART II - OTHER INFORMATION

21

 

 

Item 1.

Legal Proceedings

21

 

 

 

Item 1A.

Risk Factors

21

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

21

 

 

 

Item 3.

Defaults Upon Senior Securities

21

 

 

 

Item 4.

Mine Safety Disclosure

21

 

 

 

Item 5.

Other Information

21

 

 

 

Item 6.

Exhibits

22

 

 

 

SIGNATURES

23


PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

The following unaudited interim condensed consolidated financial statements of Yo-Health, Inc. (referred to herein as the “Company,” “we,” “us” or “our”) are included in this Quarterly Report on Form 10-Q (the “Quarterly Report”).

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States and the rules of the Securities and Exchange Commission (the “SEC”), and should be read in conjunction with the audited condensed financial statements and notes thereto contained in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2022 which we filed with the SEC on June 12, 2023 (the “Annual Report”), as updated in subsequent filings we have made with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position, and the results of operations for the periods presented have been reflected herein. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.


1


 

 

Yo-Health, Inc.

Condensed Consolidated Balance Sheets

 

 

 

 

 

 

 

 

 

 

September 30,

December 31,

 

 

 

2023

2022

 

 

 

 

(Unaudited)

 

Current assets

 

 

 

 

    Cash and cash equivalents

 

 

    Cash

 

 

$195,803  

$124,062  

    Accounts receivable

 

-  

179,298  

        Total current assets

 

195,803  

303,361  

 

 

 

    Property plant and equipment, net

3,442,091  

4,017,136  

    Intangible assets

 

40,799  

37,999  

    Right of use assets

 

900,422  

776,405  

    Other assets

 

 

6,630  

1,200  

    Security deposits

 

29,150  

29,150  

Total Assets

 

 

$4,614,894  

$5,165,250  

 

 

 

 

 

 

Current liabilities

 

 

 

 

    Accounts payable and accrued expenses

$225,944  

$59,233  

    Lease liabilities short term

204,116  

188,113  

    Line of credit

 

 

484,490  

61,490  

    Notes payable related parties

255,700  

-  

        Total current liabilities

1,170,249  

308,836  

    Long term lease liabilities

737,789  

610,930  

    Mortgage liabilities

 

1,549,713  

1,728,883  

Total Liabilities

 

 

3,457,751  

2,648,649  

 

 

 

 

 

 

Stockholders' Equity

 

 

 

Common stock, $0.0001 par value; 100,000,000 shares authorized, 77,226,355 and 70,590,898 outstanding as of September 30, 2023 and December 31 2022, respectively

7,723  

7,059  

Additional paid- in capital

20,301,605  

16,984,590  

Accumulated deficit

 

(19,152,185) 

(14,475,048) 

Total Stockholders' Equity

 

1,157,143  

2,516,601  

Total Liabilities and Stockholders' Equity

$4,614,894  

$5,165,250  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


2


 

Yo-Health, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Three Months

 

Nine Months

Nine Months

 

 

 

 

Ended

Ended

 

Ended

Ended

 

 

 

 

September 30,

September 30,

 

September 30,

September 30,

2023

2022

 

2023

2022

Revenue

$2,500,311  

$201,359  

 

$5,718,680  

$388,253  

Cost of revenue

1,589,775  

326,564  

 

4,303,560  

1,189,047  

Gross profit (loss)

$910,536  

(125,204) 

 

1,415,120  

(800,793) 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

    General and administrative expenses

1,725,370  

3,411,220  

 

5,442,108  

8,856,872  

    Professional fees

54,723  

54,605  

 

254,278  

159,341  

    Rent expense

57,007  

62,938  

 

193,259  

166,490  

    Total operating expenses

1,837,100  

3,528,763  

 

5,889,645  

9,182,703  

Loss from operations

(926,564) 

(3,653,967) 

 

(4,474,525) 

(9,983,497) 

Other income(expense)

 

 

 

 

 

     Interest expense

(25,718) 

(11,290) 

 

(95,869) 

(34,024) 

     Interest income

-  

1,817  

 

-  

1,817  

     Gain on the sale of building

-  

-  

 

438  

-  

Other expense, net

(25,718) 

(9,472) 

 

(95,431) 

(32,207) 

Loss before provision for income taxes

(952,282) 

(3,663,439) 

 

(4,569,957) 

(10,015,704) 

Provision (credit) for income tax

-  

-  

 

-  

-  

Loss from continuing operations

(952,282) 

(3,663,439) 

 

(4,569,957) 

(10,015,704) 

Income (loss) from discontinued operations

-  

9,047  

 

(107,180) 

208,938  

Net loss

$(952,282) 

$(3,654,392) 

 

$(4,677,137) 

$(9,806,766) 

 

 

 

 

 

 

Basic and diluted (loss) per common share:

 

 

 

 

 

Loss from continuing operations

$(0.01) 

$(0.05) 

 

$(0.06) 

$(0.16) 

Income (loss) from discontinued operations

$-  

$0.00  

 

$(0.00) 

$0.00  

 

 

 

 

 

 

Weighted average number of shares outstanding

76,661,355  

67,338,998  

 

75,054,536  

62,272,998  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


3


 

 

Yo-Health, Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity

For the Nine Months Ended September 30, 2023 and September 30, 2022

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

Accumulated

 

Total

 

Common Stock

 

Paid-in

 

Earnings

 

Stockholders'

Shares

 

Amount

 

Capital

 

(Deficit)

 

Equity

Balance, December 31, 2021

51,232,998 

 

$5,123 

 

$7,159,526 

 

$(3,593,926) 

 

$3,570,723  

 

 

 

 

 

 

 

 

 

 

Shares issued for services

10,000 

 

1 

 

4,999 

 

 

 

5,000  

 

 

 

 

 

 

 

 

 

 

Issuance of common stock and warrants in private placements

898,000 

 

90 

 

505,110 

 

 

 

505,200  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(520,868) 

 

(520,868) 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2022

52,140,998 

 

$5,214 

 

$7,669,635 

 

$(4,114,794) 

 

$3,560,055  

 

 

 

 

 

 

 

 

 

 

Shares issued for services

10,240,500 

 

1,024 

 

5,119,226 

 

 

 

5,120,250  

 

 

 

 

 

 

 

 

 

 

Issuance of common stock and warrants in private placements

1,868,500 

 

187 

 

1,019,613 

 

 

 

1,019,800  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(5,631,505) 

 

(5,631,505) 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2022

64,249,998 

 

$6,425 

 

$13,808,474 

 

$(9,746,299) 

 

$4,068,600  

 

 

 

 

 

 

 

 

 

 

Shares issued for services

6,108,000 

 

611 

 

3,059,639 

 

 

 

3,060,250  

 

 

 

 

 

 

 

 

 

 

Issuance of common stock and warrants in private placements

70,000 

 

7 

 

34,993 

 

 

 

35,000  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(3,654,392) 

 

(3,654,392) 

 

 

 

 

 

 

 

 

 

 

Balance, September 30, 2022

70,427,998 

 

$7,043 

 

$16,903,106 

 

$(13,400,692) 

 

$3,509,457  

 

 

 

 

 

 

 

 

 

 

 

Shares

 

Amount

 

Capital

 

(Deficit)

 

Equity

Balance, December 31, 2022

70,590,898 

 

$7,059 

 

$16,984,590 

 

$(14,475,048) 

 

$2,516,601  

 

 

 

 

 

 

 

 

 

 

Stock based compensation

1,110,000 

 

111 

 

554,889 

 

 

 

555,000  

 

 

 

 

 

 

 

 

 

 

Issuance of common stock and warrants in private placements

140,000 

 

14 

 

69,985 

 

 

 

70,000  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(837,652) 

 

(837,652) 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2023

71,840,898 

 

$7,184 

 

$17,609,464 

 

$(15,312,700) 

 

$2,303,949  

 

 

 

 

 

 

 

 

 

 

Stock based compensation

4,255,457 

 

426 

 

2,127,254 

 

 

 

2,127,680  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(2,887,203) 

 

(2,887,203) 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2023

76,096,355 

 

$7,610 

 

$19,736,718 

 

$(18,199,903) 

 

$1,544,424  

 

 

 

 

 

 

 

 

 

 

Stock based compensation

1,130,000 

 

113 

 

564,887 

 

 

 

565,000  

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

(952,282) 

 

(952,282) 

 

 

 

 

 

 

 

 

 

 

Balance, September 30, 2023

77,226,355 

 

$7,723 

 

$20,301,605 

 

$(19,152,185) 

 

$1,157,143  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


4


 

Yo-Health, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

 

Nine Months

Nine Months

 

Ended

Ended

 

September 30,

September 30,

2023

2022

Cash Flows From Operating Activities:

 

 

    Loss from continuing operations

$(4,569,957) 

$(10,015,704) 

    Less: income (loss) from discontinued operations

(107,180) 

208,938  

    Net loss

(4,677,137) 

(9,806,766) 

    Stock based compensation

3,247,680  

8,185,500  

    Depreciation

232,222  

34,971  

    Gain on the sale of building

(438) 

 

    Changes in operating assets and liabilities

 

 

    Accounts receivable

179,298  

110,678  

    Accounts receivable other

-  

7,400  

    Subscriptions receivable

-  

20,000  

    Other assets

(5,430) 

-  

    Security deposits

-  

(6,700) 

    Accounts payable and accrued liabilities

175,305  

50,926  

    Mortgage payable

(34,171) 

106,611  

Net cash used in operating activities -continuing operations

(882,670) 

(1,297,380) 

Net cash provided by (used in) operating activities -discontinued operations

-  

-  

    Net cash (used in) operating activities

(882,670) 

(1,297,380) 

 

 

 

Cash flows from Investing Activities

 

 

     Property and equipment -asset purchase

(49,289) 

(410,312) 

     Cash flows (used in) investing activities

(49,289) 

(410,312) 

 

 

 

Cash Flows From Financing Activities:

 

 

    Proceeds from line of credit

423,000  

-  

    Notes payable related parties

255,700  

-  

    Proceeds from the sale of property

255,000  

-  

    Proceeds from the sale of common stock

70,000  

1,560,000  

    Net cash provided by investing activities

1,003,700  

1,560,000  

 

 

 

Net Increase (Decrease) In Cash

71,741  

(147,692) 

Cash At The Beginning Of The Period

124,062  

1,429,587  

Cash At The End Of The Period

$195,803  

$1,281,895  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


5


 

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Nature of Operations

 

YO-Health, Inc. (“YO-Health” or the “Company”) was established as a C-Corporation in Nevada on October 22, 2020. The Company is the parent company to Yoshi Inc, Sun & Moon Café, 7K Farms and Joyce’s Bakery Inc. YO-Health manufactures, retails, wholesales, and distributes premium, healthy, unique, and innovative food products.

 

The Company commenced operations in October 2020 by acquiring a Beijing-style premium yogurt store in Woodside, New York. The Company has since launched the subsidiaries Yoshi Restaurants, Inc., Sun & Moon, and Joyce’s Bakery & Café, Inc.

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc.

 

The Company currently has 4 Yoshi model restaurants, 1 Sun & Moon Café and 1 yogurt manufacturing facility.

 

Each subsidiary company of YO-Health, Inc. will focus on their respective products on a wholesale and retail basis:

 

Sun & Moon will produce, market, and sell yogurt-based items with probiotics and ingredients focused on beneficial healthy products.

 

Yoshi will produce, market, and sell Asian fusion food products.

 

Joyce’s Bakery & Café will produce, market, and sell premium, Asian- French-inspired desserts, Tea’s, Juices, and flavored coffee with a full array of non-alcoholic drinks.

 

7K Farms delivers wholesale food and supplies to the Company locations as well as other restaurant and grocery locations.

 

On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation -see Note 4. Discontinued Operations.

 

The Company’s accounting year-end is December 31.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The condensed consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Yoshi Inc, Sun & Moon Café, and Joyce’s Bakery Inc.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed consolidated financial statements.


6


 

For the nine months ended September 30, 2023, the Company had a loss from continuing operations of $4,569,957. As of September 30, 2023 the Company had an accumulated deficit of $19,152,185. The Company expects to generate operating cash flows that will be sufficient to fund presently anticipated operations although there can be no assurance. This raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing to supplement the expected cash flow.

 

Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its revenues support its operations.

 

The Company may attempt to raise capital in the near future through the sale of equity or debt financing; however, there can be assurances the Company will be successful in doing so. There can be no assurance that such additional financing will be available to the Company on acceptable terms or at all.

 

Management’s Representation of Interim Condensed Consolidated Financial Statements

 

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual condensed financial statements. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed financial statements include all of the adjustments, which in the opinion of management are necessary for a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of goodwill, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable, and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Segment Reporting

 

The Company operates in one segment, the food service business. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying condensed consolidated financial statements.


7


 

Goodwill and Intangible Assets

 

Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter.

 

Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill and indefinite-lived assets during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry, and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.

 

Indefinite-lived intangible assets are evaluated for impairment at the individual asset level by assessing whether it is more likely than not that the asset is impaired (for example, that the fair value of the asset is below its carrying amount). If it is more likely than not that the asset is impaired, its carrying amount is written down to its fair value.

 

Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.

 

We performed our annual fair value assessment on December 31, 2021, on our purchases of the New Orleans, Woodside, 7K Farms and the Champagne, Illinois acquisitions, and determined that an impairment charge of $750,000 and $1,000,000, respectively, was necessary for the years ended December 31, 2022, and 2021. As a result, we had no goodwill as of September 30, 2023, and December 31, 2022, respectively. The balance of indefinite-lived intangible assets comprised of trademarks were $40,799 and $37,399, respectively, as of September 30, 2023, and December 31, 2022.


8


 

Revenue Recognition

 

The Company recognizes revenue under the guidelines of ASC 606. Sales, as presented in the Company’s statement of earnings, represent revenue; and food and beverage products sold which is presented net of discounts, coupons, employee meals and complimentary meals. Revenue is recognized using the five step approach required under the guidelines of ASC 606:

 

1.Identify the contract with the client, 

 

2.Identify the performance obligations in the contract, 

 

3.Determine the transaction price, 

 

4.Allocate the transaction price to performance obligations in the contract 

 

5.Recognize revenues when or as the Company satisfies a performance obligation 

 

For retail operations, all five steps of revenue recognition occur almost simultaneously. The customer orders food from a menu or store sign, it is given to the customer who then pays for the food order at the cash register. The Company’s store business represented approximately 27.6% and 100% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

 

For wholesale sales the customer orders wholesale items from a store sign or catalogue, it is given or delivered to the customer who then pays for the items within 7 days of sale. The Company’s store business represented approximately 72.4% and 0% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On September 30, 2023, and December 31, 2022, the Company’s cash equivalents totaled $195,803 and $124,062 , respectively.

 

Property and equipment

 

Property and equipment are stated at cost or fair value. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expenses as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in the results of operations. The estimated useful lives of property and equipment are as follows:

 

Computers, software, and office equipment

1 – 6 years

Machinery and equipment

3 – 5 years

Leasehold improvements

Lesser of lease term or estimated useful life

Buildings

39 years

 

Equipment that hasn’t been placed into service is not subject to depreciation.

 

Depreciation expense for the nine months ended September 30, 2023 and 2022 was $232,222 and $23,314, respectively.


9


 

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

 

Leases

The Company currently follows the guidance in ASC 840 “Leases,” which requires us to evaluate the lease agreements the Company enters into to determine whether they represent operating or capital leases at the inception of the lease.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), that requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The accounting treatment for finance leases and lessors remains relatively unchanged. The accounting standards update also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB approved an amendment to the new guidance that introduced an alternative modified retrospective transition approach granting companies the option of using the effective date of the new standard as the date of initial application. The Company adopted the standard using the effective date method on December 31, 2022.

The Company elected the transition package of practical expedients that is permitted by the standard. The package of practical expedients allows the Company to not reassess previous accounting conclusions regarding whether existing arrangements are or contain leases, the classification of existing leases, and the treatment of initial direct costs. The Company did not elect the hindsight transition practical expedient allowed for by the new standard, which allows entities to use hindsight when determining lease term and impairment of ROU assets. Additionally, the Company elected certain other practical expedients offered by the new standard which it will apply to all asset classes, including the option not to separate lease and non-lease components and instead to account for them as a single lease component and the option not to recognize ROU assets and related liabilities that arise from short-term leases (i.e., leases with terms of twelve months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise).

The standard had a material impact on the balance sheet on the date of adoption, with the most significant impact being the recognition of $900,422 operating lease right-of-use assets and $204,116 operating lease liabilities.

 

As part of its adoption of the new lease accounting standard, the Company also implemented new internal controls and updated accounting policies and procedures, operational processes and documentation practices to enable the preparation of financial information on adoption. Refer to Note 6: Leases - Accounting Principles and Leases for additional disclosures required as a result of the adoption of this new standard.

 

Stock Purchase Warrants

 

The Company has issued warrants to purchase shares of its common stock. Warrants have been accounted for as equity in accordance with FASB ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the


10


enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

On Dec. 18, 2019, the Financial Accounting Standards Board (FASB) released Accounting Standards Update (ASU) 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The FASB has stated that the ASU is being issued as part of its Simplification Initiative, which is meant to reduce complexity in accounting standards by improving certain areas of generally accepted accounting principles (GAAP) without compromising information provided to users of condensed consolidated financial statements. The Company adopted this guidance on January 1, 2021, which had no impact on the Company’s condensed consolidated financial statements.

 

Net Loss per Share

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, "Earnings per Share." Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and diluted common share equivalents outstanding.

 

Discontinued Operations

 

The operations of the Company’s former Winn Sushi Division has been presented as discontinued operations. Unless otherwise noted, amounts and disclosures throughout these Notes to Condensed Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 4. for additional information on discontinued operations.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard. On November 15, 2019, the FASB has issued ASU 2019-10, which amends the effective dates for three major accounting standards. The ASU defers the effective dates for the credit losses, derivatives, and lease standards for certain companies.   The Company adopted ASC 842 on December 31, 2022.


11


 

NOTE 3 – PROPERTY, PLANT, AND EQUIPMENT

 

The following table sets forth the components of the Company’s property and equipment on September 30, 2023, and December 31, 2022:

 

 

 

September 30, 2023

 

 

December 31, 2022

 

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

Computers, software, property, and equipment

 

 

$3,761,670 

 

 

 

$(469,579) 

 

 

 

$3,292,091 

 

 

 

$4,060,518 

 

 

 

$(242,382) 

 

 

 

$3,818,136 

 

Land

 

 

150,000 

 

 

 

-  

 

 

 

150,000 

 

 

 

199,000 

 

 

 

-  

 

 

 

199,000 

 

Total fixed assets

 

 

$3,911,670 

 

 

 

$(469,579) 

 

 

 

$3,442,091 

 

 

 

$4,259,518 

 

 

 

$(242,382) 

 

 

 

$4,017,136 

 

 

On September 21, 2021 the Company entered into an Exchange Agreement with Yoshi Properties, LLC, an Ohio limited liability company and its sole members, Peter and Vila Thawnghmung who are both officers and directors of the Company, and related parties. Under the terms of the Exchange Agreement the Company purchased ownership of all of the membership interests (100%) in Yoshi Properties, comprised solely of two properties and the related mortgages for consideration of 1,000,000 shares of the Company’s common stock. No other assets or liabilities were included in the purchase price.

 

The fair market value of the properties acquired from Yoshi Properties, LLC was estimated to be equivalent to the mortgages assumed, or approximately $695,000. The 1,000,000 shares issued to Yoshi Properties was recorded at a value of $0.50 per share which was equivalent to the price of $0.50 per share paid by investors in the Company’s private placement offering of common stock at that time. As a result the Company recorded $500,000 in stock-based compensation expenses on its Statements of Operations for the year ended December 31, 2021.

 

NOTE 4 – DISCONTINUED OPERATIONS

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation.

 

The components of the loss from discontinued operations for the three and nine months ended September 30, 2023, and 2022 in the statement of operations consisted of the following:

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

2023

 

2022

 

2023

 

2022

Revenue

$- 

 

$746,462 

 

$866,247  

 

$2,069,135 

Cost of goods sold

- 

 

715,906 

 

798,911  

 

1,834,625 

Gross Profit

- 

 

30,556 

 

67,336  

 

234,510 

Operating expenses

- 

 

21,509 

 

174,516  

 

25,572 

Discontinued operations, net of tax

$- 

 

$9,047 

 

$(107,180) 

 

$208,938 


12


 

NOTE 5 – MORTGAGES PAYABLE

 

The balance in mortgages payable was $1,549,713 and $1,728,883 as of September 30, 2023, and December 31, 2022, respectively. The mortgage balance as of September 30, 2023, is comprised of:

 

·Mortgage Loans: CNB Bank- OH Store = $ 270,466 

·Mortgage Loans: Old National Bank- LA Store/Fac = $ 525,380 

·Mortgage Loans: Old National Loan- IN Factory = $ 260,240 

·Mortgage Loans: Old National – 7K farms - Mtg = $ 493,627 

 

Interest expense on these mortgages were $66,522 and $34,024, for the nine months ended September 30, 2023, and September 30, 2022, respectively. The interest expense balance as of September 30, 2023, is comprised of:

 

·Interest Expense: OH Store- CNB Bank = $ 15,647 

oInterest Rate: 7.34% 

·Interest Expense: LA Store/Factory- Old National = $ 16,239 

oInterest Rate: 4% 

·Interest Expense: IN Factory- Old National = $ 8,046 

oInterest Rate: 4% 

·Interest Expense: 7K Farms RE - Old National = $ 26,590 

oInterest Rate: 6.5% 

 

On September 30, 2023, the aggregate maturities of notes payable for the next five years and thereafter are as follows:

 

2022

 

$

 -

2023

 

 -

2024

 

$

 -

2025

 

$

 -

2026 and thereafter

 

$

1,549,713 

Total

 

$

1,549,713 

 

NOTE 6 – RELATED PARTY TRANSACTIONS

 

Peter Thawnghmung, the Company’s Chairman and CEO is the spouse of Vila Thawnghmung, who is a director of the Company. The Company has 4 directors, therefore, Peter and Vila Thawnghmung, two of those directors can control all Company activity. Peter and Vila Thawnghmung have personally guaranteed all of the mortgages on the real properties owned by the Company and its subsidiaries as well as the Line of Credit. Arianna Phrakornkham, their daughter, is the controller of the Company.

 

In 2021 Peter and Vila Thawnghmung received 1,048,000 common shares for services performed. These shares were valued at $524,000. Related parties to Peter and Vila Thawnghmung received 120,000 common shares for services valued at $60,000.

 

In 2022 Peter and Vila Thawnghmung received 9,051,000 common shares for services performed. These shares were valued at $4,525,500. Arianna Phrakornkham received 1,000,000 shares valued at $500,000 for services. Related parties to Peter and Vila Thawnghmung received 1,127,000 common shares valued at $63,500.

 

During the nine months ended September 30, 2023, Peter and Vila Thawnghmung received 68,000 shares for service performed. These share were valued at $34,000. During this period, Rome Thalop, who was appointed a director on March 23, 2023, received 16,000 shares valued at $8,000 for his ongoing services as a director.


13


 

NOTE 7 – LINE OF CREDIT

 

As of September 30, 2023, the Company has one line of credit with Old National Bank. The interest rate is 8.75% with a credit limit of $500,00 and a loan term of 24 months. The loan originated on 10/31/2022 and expires on 10/31/2024. The line of credit is collateralized by 7K Farms and was personally guaranteed by Peter and Vila Thawnghmung. The balance of the line of credit was $484,900 and $61,490 as of September 30, 2023 and September 30, 2022, respectively.

 

NOTE 8 – LEASES

 

As of September 30, 2023, the Company had signed 6 long-term leases:

 

·Flushing, New York: The Company entered into a lease for $7,500/month with a lease term of 5 years (11/25/2020 – 11/15/2025). 

·Columbus, Ohio: The Company entered into a lease for $3,370.83/month with a lease term of 7 years (6/4/2021 – 3/31/2028). 

·Indianapolis, Indiana: The Company entered into a lease for $3,065.75/month with a lease term of 5 years (5/1/2021 – 4/30/2026). 

·Indianapolis, Indiana: The Company entered into a lease for $4,200/month with a lease term of 6 years (6/1/2022 – 5/31/2028). 

·Indianapolis, Indiana: The Company entered into a lease for $4,911.83/month with a lease term of 5 years (5/1/2023 – 10/31/2028). 

·Columbus, Ohio: The Company entered into a lease for $3,798/month with a lease term of 5.6 years (9/1/2023 – 4/31/2029). 

 

Accounting Principles

 

Under ASC 842, the determination of whether an arrangement is a lease is made at the lease’s inception and a contract is (or contains) a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is defined under the standard as having both the right to obtain substantially all of the economic benefits from use of the asset and the right to direct the use of the asset. Management only reassesses its determination if the terms and conditions of the contract are changed. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our balance sheets.

 

ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when it is readily determinable. Since most of the Company’s leases do not provide an implicit rate, to determine the present value of lease payments, management uses the Company’s incremental borrowing rate based on the information available at lease commencement. Operating lease ROU assets also include any lease payments made and exclude any lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option, with renewal options that can extend the lease from three to five years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.

 

The Company has lease agreements with lease and non-lease components, for which it has made an accounting policy election to account for these as a single lease component.

Leases

 

The Company leases retail spaces under operating lease agreements that have term lengths of five to seven years and that have renewal options that range from three to five years. The Company pays certain variable lease costs such as real estate taxes, insurance, and common area maintenance charges. The Company accounts for lease and non-lease components as a single lease component.


14


 

 

Lease Cost

 

 

 

 

 

Operating lease cost

 

220,622

 

Short-term lease cost

 

 

3,854

 

Variable lease cost

 

 

27,166

 

Total lease cost

 

$

251,642

 

 

The weighted average remaining lease term for operating leases is 3.73 years and the weighted average discount rate for operating leases is 4%.

 

Maturities of lease liabilities as of September 30, 2023, were as follows:

 

 

 

Operating

 

 

 

Leases

 

2023

 

$

 

2024

 

 

212,833

 

2025

 

 

208,660

 

2026

 

 

103,114

 

2027

 

 

95,650

 

Thereafter

 

 

33,112

 

 

 

 

809,679

 

Less imputed interest

 

 

70,124

 

Total

 

$

739,555

 

 

Operating cash flows from operating leases for the year ended December 31, 2022, was $197,187, and lease assets were obtained in exchange for operating lease liabilities for the year ended December 31, 2022, of $693,230.

 

NOTE 9 – EQUITY

 

The Company has authorized 100,000,000 shares of par value of $0.0001 common stock. As of September 30, 2023, and December 31, 2022, the Company had 77,226,355 and 70,590,898 common shares issued and outstanding, respectively.

 

September 30, 2023 Activity

 

During the nine months ended September 30, 2023, the Company had the following common stock transactions:

 

·Issuance of 6,375,357 shares for services valued at $3,187679

 

·Issuance of 260,000 shares in private placements valued at $130,000

 

December 31, 2022 Activity

 

During the year ended December 31, 2022, the Company had the following common stock transactions:

 

·Issuance of 2,773,900 shares in private placements valued at $1,534,999

 

·Issuance of 15,584,000 shares for services valued at $7,792,000

 

·Issuance of 1,000,000 shares for the purchase of 7K Farms valued at $500,000


15


 

Warrants

 

As of September 30, 2023, the Company had 6,059,998 warrants outstanding, all with a strike price of $1.25. The warrants have a two-year term and expire at varying times between September 30, 2023 and June 13, 2025.

 

A summary of the status of the outstanding stock warrants is presented below:

 

Exercise Price

 

 

Number Outstanding

9/30/2023

 

 

Weighted Average

Remaining Contractual Life

 

 

Weighted Average

Exercise Price

$1.25

 

 

6,059,998

 

 

0.39 years

 

 

$1.25

 

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

Legal Proceedings

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana.

 

NOTE 11 – SUBSEQUENT EVENTS

 

As of September 30, 2023, the Company had 77,226,355 shares of its common stock issued and outstanding. Subsequent to September 30, 2023, the Company had 77,717,721 shares of its common stock issued and outstanding. From October 1, 2023 – March 5, 2024, an additional 491,366 shares were issued, 431,366 shares were for services.


16


 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The information outlined in this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including, among others (I) increase in our revenue and profitability, (ii) prospective business opportunities and (iii) our strategy for financing our business. Forward-looking statements are statements other than historical information or statements of current condition. Some forward-looking statements may be identified by use of terms such as “believes”, “anticipates”, “intends” or “expects”. These forward-looking statements relate to our plans, liquidity, ability to complete financing, to enter into future agreements with companies, and plans to successfully expand our business operations and the sale of our products. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 

Although we believe that our expectations with respect to the forward-looking statements are based upon reasonable assumptions within the bounds of our knowledge of our business and operations, in light of the risks and uncertainties inherent in all future projections, the inclusion of forward-looking statements in this Quarterly Report should not be regarded as a representation by us or any other person that our objectives or plans will be achieved. All forward-looking statements speak only as of the date of this Quarterly Report. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, or other information contained herein, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance.

 

Basis of Presentation

 

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on our unaudited condensed consolidated financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such condensed financial statements and the related notes thereto.

 

The audited condensed financial statements for our fiscal year ended December 31, 2022, contained in our Annual Report, include a summary of our significant accounting policies and should be read in conjunction with the discussion below. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in these audited condensed financial statements. All such adjustments are of a normal recurring nature.

 

References in this section to “Yo-Health,” “we,” “us,” “our,” “the Company” and “our Company” refer to Yo-Health, Inc.

 

Overview

 

YO-Health, Inc. (“YO-Health” or the “Company”) was established as a C-Corporation in Nevada on October 22, 2020. The Company is the parent company to Yoshi Inc, Sun & Moon Café, 7K Farms and Joyce’s Bakery Inc. YO-Health manufactures, retails, wholesales, and distributes premium, healthy, unique, and innovative food products.

 

The Company commenced operations in October 2020 by acquiring a Beijing-style premium yogurt store in Woodside, New York. The Company has since launched the subsidiaries Yoshi Restaurants, Inc., Sun & Moon, and Joyce’s Bakery & Café, Inc. The Company currently has 4 Yoshi model restaurants, and 1 yogurt manufacturing facility.


17


Each subsidiary company of YO-Health, Inc will focus on their respective products on a wholesale and retail basis:

Sun & Moon will produce, market, and sell yogurt-based items with probiotics and ingredients focused on beneficial healthy products.

·Yoshi will produce, market, and sell Asian fusion food products. 

 

·Joyce’s Bakery & Café will produce, market, and sell premium, Asian- French-inspired desserts, Tea’s, Juices, flavored coffee with a full array of non-alcoholic drinks. 

 

·7K Farms delivers wholesale food and supplies to the Company locations as well as other restaurant and grocery locations. 

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023 the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result Win Sushi became a discontinued operation -see Note 4. Discontinued Operations.

 

Results of Operations

 

The results from discontinued operations are excluded from management’s discussion of operations below, and from the Liquidity analysis.

 

Comparison of Results of Operations for the Three Months Ended September 30, 2023 and 2022

 

Revenue and Cost of Sales

 

During the three months ended September 30, 2023 revenues were $2,500,311 compared to revenue of $201,359 for the three months ended September 30, 2022. The increase is attributable to the addition of new business and locations in the 2023 period.

 

Cost of revenue was $1,589,775, for the three months ended September 30, 2023, compared to the cost of revenue of $326,564 for the three months ended September 30, 2022. The increase is attributable to higher levels of sales.

 

Operating expenses

 

Operating expenses for the three months ended September 30, 2023, were $1,837,100 compared to $3,528,763 for the three months ended September 30, 2022. Operating expenses include $555,000 and $3,060,250 in stock-based compensation for the three month periods ended September 30, 2023 and September 30, 2022, respectively. Excluding stock base compensation operating expenses were $1,282,100 and $468,513, respectively for the periods ended September 30, 2023 and 2022. The increase in the 2023 period is attributable to the addition of expenses associated with new lines of business during the 2023 period.

 

Net (Loss) Income

 

As a result of the foregoing, we recorded a loss of $952,282 or $(0.01) per share from continuing operations for the three months ended September 30, 2023, compared to an operating loss of $3,654,392 or $(0.05) per share from continuing operations for the three months ended September 30, 2022.


18


 

Comparison of Results of Operations for the Nine Months Ended September 30, 2023 and 2022

 

Revenue and Cost of Sales

 

During the nine months ended September 30, 2023 revenues were $5,718,680 compared to revenue of $388,253 for the nine months ended September 30, 2022. The increase is attributable to the addition of new business and locations in the 2023 period.

 

Cost of revenues was $4,303,560 for the nine months ended September 30, 2023 compared cost of revenue of $1,189,047 for the nine months ended September 30, 2022. The increase is attributable to higher levels of sales.

 

Operating expenses

 

Operating expenses for the nine months ended September 30, 2023 were $5,889,645 compared to $8,856,872 for the nine months ended September 30, 2022. Operating expenses include $3,247,680 and $8,185,500 in stock based compensation for the nine month periods ended September 30, 2023 and September 30, 2022, respectively. Excluding stock base compensation, operating expenses were $2,641,965 and $997,203, respectively, for the periods ended September 30, 2023 and 2022. The increase in the 2023 period is attributable to the addition to expenses associated of new lines of business during the 2023 period.

 

Net (Loss) Income

 

As a result of the foregoing we recorded a loss of $4,569,957 or $(0.06) per share from continuing operations for the nine months ended September 30, 2023 compared to an operating loss of $9,806,777 or $(0.16) per share from continuing operations for the nine months ended September 30, 2022.

 

Liquidity and Capital Resources

 

As of September 30, 2023 our cash balance was $195,803.

 

Cash used in operating activities was $882,670 for the nine months ended September 30, 2023 compared to $1,297,380 of cash used in operating activities during the nine months ended September 30, 2022. The decrease in cash used in operating activities is attributable to an improvement in profitability net of non-cash stock-based compensation in the 2023 period compared to the 2022 period, and due to an increase in net operating assets and liabilities.

 

Cash flows used in investing activities was $49,289 and $410,312, respectively for the nine months ended September 30, 2023 and September 30, 2022, respectively due to the purchase of fixed assets during the 2022 period.

 

Cash flows from financing activities was $1,003,700 during the nine months ended September 30, 2023 compared to $1,560,000 during the nine months ended September 30, 2022. During the 2023 period the Company received proceeds of $423,000 from its line of credit, $255,000 from the sale of a building,$255,700 in related party loans and $70,000 in proceeds from the sale of common stock, compared to $1,560,000 from the sale of common stock in the 2022 period.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed financial statements. On a basis, we have incurred significant operating losses since inception. The Company’s independent auditor has indicated substantial doubt about the Company continuing as a going concern based on the Company’s accumulated deficit and accrued liabilities. Our ability to continue our operations as a going concern, realize the carrying value of our assets, and discharge our liabilities in the normal course of business is dependent upon our ability to raise capital sufficient to fund our commitments and ongoing losses, and ultimately generate profitable operations. If we cannot obtain the needed funds, we may be forced to reduce or cease our activities with a consequent loss to investors. In addition,


19


should we incur significant presently unforeseen expenses or delays, we may not be able to accomplish our goals. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Critical Accounting Estimates

 

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with GAAP. The preparation of these condensed financial statements requires management to make estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare our condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position. Our critical accounting estimates are more fully discussed in Note 2. to our unaudited condensed financial statements contained herein.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable because we are an emerging growth company.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this Quarterly Report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Secretary/Treasurer (Chief Financial Officer), we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Securities and Exchange Act of 1934 Rule 13(a)-15(e). Disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act has been appropriately recorded, processed, summarized and reported on a timely basis and are effective in ensuring that such information is accumulated and communicated to the Company’s management, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that as of September 30, 2023, our disclosure controls and procedures are not effective.

 

Management has identified the following material weaknesses in our internal control over financial reporting:

 

Management has concluded that there is a material weakness due to the control environment. The control environment is impacted due to the company’s inadequate segregation of duties, including information technology control activities.

 

Since the assessment of the effectiveness of our internal control over financial reporting did identify material weaknesses, management considers its internal control over financial reporting to be ineffective.

 

In an effort to remediate the identified material weakness and enhance our internal control over financial reporting, we have hired additional personnel to help ensure that we are able to properly implement internal control procedures.

 

Management believes that the material weakness set forth above did not have an effect on our financial results.


20


 

Changes in Internal Control over Financial Reporting

 

None

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

For a discussion of legal proceedings, see “– Legal Proceedings” in Note 8 to the Condensed Consolidated Financial Statements in Part I, Item 1 of this report, which section is incorporated by reference herein.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the nine months ended September 30, 2023, the Company had the following common stock transactions:

 

Issuance of 6,495,357 shares for services valued at $3,247,680.

 

Issuance of 140,000 shares in private placements valued at $70,000.

 

These issuances were exempt from registration under Section 4(a)(2) of the Securities Act as not involving any public offering.

 

Item 3. Defaults upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

On April 21, 2023, the Company’s board of directors adopted a Code of Business Conduct and Ethics (“Code of Ethics”) that applies to its officers, directors, and employees. A copy of the Code of Ethics is filed as Exhibit 14.1 to this Quarterly Report.


21


 

Item 6. Exhibits.

 

Exhibit No.

 

Description

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) (filed herewith)

 

 

 

31.2

 

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) (filed herewith)

 

 

 

32.1

 

Certification pursuant to 18 U.S.C. Section 1350 (furnished herewith)

 

 

 

101.INS

 

Inline XBRL Instance Document*

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document*

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document*

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document*

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*Filed herewith


22


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

YO-HEALTH, INC.

 

 

 

Date: March 18, 2024

By:

/s/ Peter Thawnghmung

 

Name: 

Peter Thawnghmung, CEO

 

Title:

Chief Financial Officer, President,
Secretary and Treasurer

(Principal Executive Officer and
Principal Financial and Accounting Officer)


23

EX-31.1 2 yohe_ex31z1.htm CERTIFICATION

EXHIBIT 31.1 

 

CERTIFICATION

 

I, Peter Thawnghmung, certify that:

 

1.I have reviewed this Form 10-Q of YO-Health, Inc.; and 

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

 

 

Date: March 18, 2024

/s/ Peter Thawnghmung

 

Peter Thawnghmung

 

Chief Executive Officer

 

(Principal Executive Officer)

 

EX-31.2 3 yohe_ex31z2.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION

 

I, Vilayphone Thawnghmung, certify that:

 

1.I have reviewed this Form 10-Q of YO-Health, Inc.; and 

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

 

 

Date: March 18, 2024

/s/ Vilayphone Thawnghmung

 

Vilayphone Thawnghmung

 

Secretary/Treasurer

 

(Principal Financial Officer)

 

EX-32.1 4 yohe_ex32z1.htm CERTIFICATION

EX-32.1

 

 

CERTIFICATION PURSUANT TO

U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Peter Thawnghmung, the Chief Executive Officer of YO-Health, Inc. (the “Registrant”) and Vilayphone Thawnghmung, the Secretary/Treasurer of the Registrant, each hereby certifies that, to the best of his knowledge:

 

1.The Registrant’s Annual Report on Form 10-Q for the period ended September 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended and 

 

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Registrant at the end of the period covered by the Periodic Report and results of operations of the Registrant for the periods covered by the Periodic Report. 

 

 

 

 

 

Date: March 18, 2024

/s/ Peter Thawnghmung

 

Peter Thawnghmung

 

Chief Executive Officer

 

(Principal Executive Officer)

 

 

 

 

Date: March 18, 2024

/s/ Vilayphone Thawnghmung

 

Vilayphone Thawnghmung

 

Secretary/Treasurer

 

(Principal Financial Officer)

 

EX-101.CAL 5 yohe-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 yohe-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 yohe-20230930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Operating Leases, Future Minimum Payments Due, Gross Represents the monetary amount of Operating Leases, Future Minimum Payments Due, Gross, as of the indicated date. Operating Leases, Future Minimum Payments, Due in Rolling Year Three Schedule of Maturities of Lease Liabilities Net Loss Per Share Revenue Recognition NOTE 5 - MORTGAGES PAYABLE NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT Cash flows from Investing Activities Interest Expense Interest expense Security deposits Total current assets Total current assets Entity Interactive Data Current Indianapolis, Indiana - 2 Represents the Indianapolis, Indiana - 2, during the indicated time period. Real Estate, Type of Property [Axis] Debt Instrument, Description Old National Bank- LA Store/Fac Represents the Old National Bank- LA Store/Fac, during the indicated time period. Depreciation Expense on Reclassified Assets Disposal Groups, Including Discontinued Operations Proceeds from line of credit Net cash provided by (used in) operating activities -discontinued operations Represents the monetary amount of Net cash provided by (used in) operating activities -discontinued operations, during the indicated time period. Provision (credit) for income tax Professional fees Accumulated deficit Accumulated deficit Long term lease liabilities Current liabilities Entity File Number Document Quarterly Report Document Type Stock Issuance 1 Represents the Stock Issuance 1, during the indicated time period. Less: imputed interest Operating Lease, Liability Operating cash flows from operating leases Indianapolis, Indiana - 1 Represents the Indianapolis, Indiana - 1, during the indicated time period. Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three CNB Bank- OH Store Represents the CNB Bank- OH Store, during the indicated time period. Credit Facility Statistical Measurement Use of Estimates Accounts payable and accrued liabilities Subscriptions receivable Represents the monetary amount of Increase decrease in subscriptions receivable, during the indicated time period. Stock Issued During Period, Value, Issued for Services Shares, Outstanding, Beginning Balance Shares, Outstanding, Beginning Balance Shares, Outstanding, Ending Balance General and administrative expenses Total current liabilities Total current liabilities Line of credit Other assets Document Fiscal Period Focus Document Fiscal Year Focus Stock Issued During Period, Shares, Acquisitions Operating Leases, Future Minimum Payments, Next Rolling 12 Months Columbus, Ohio Represents the Columbus, Ohio, during the indicated time period. Real Estate Entity Incorporation, Date of Incorporation Entity Incorporation State Country Name Represents the description of Entity Incorporation State Country Name, during the indicated time period. Security deposits {1} Security deposits Condensed Consolidated Statements of Operations Total Liabilities Total Liabilities Property plant and equipment, net Current assets Entity Incorporation, State or Country Code Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five Recent Accounting Pronouncements Stock-based Compensation Net Increase (Decrease) In Cash Net Increase (Decrease) In Cash Other assets {1} Other assets Statement [Line Items] Equity Components [Axis] Income (loss) from discontinued operations Less: income (loss) from discontinued operations Cost of revenue Entity Address, Address Line One Related and Nonrelated Party Status [Axis] Land {1} Land Property, Plant and Equipment, Useful Life Computer Equipment Property, Plant and Equipment NOTE 6 - RELATED PARTY TRANSACTIONS Proceeds from the sale of property Stock based compensation Represents the monetary amount of Stock based compensation, Net, during the indicated time period. Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance Statement Other expense, net Other expense, net Notes payable related parties Represents the monetary amount of Notes payable related parties, as of the indicated date. Entity Address, Postal Zip Code Entity Registrant Name Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stock Issuance [Axis] Represents the description of Stock Issuance, during the indicated time period. Columbus, Ohio - 2 Represents the Columbus, Ohio - 2, during the indicated time period. Related and Nonrelated Party Status Statistical Measurement [Axis] Property and Equipment Common Stock Lease liabilities short term Right of use assets Cash Entity Common Stock, Shares Outstanding Fiscal Year End Peter and Vila Thawnghmung Represents the Peter and Vila Thawnghmung, during the indicated time period. Old National - 7K farms - Factory Represents the Old National - 7K farms - Factory, during the indicated time period. Gross Profit {1} Gross Profit Accumulated Depreciation Accumulated Depreciation Building Long-Lived Tangible Asset Schedule of lease costs and other information relating to the Company's operating leases Basis of Presentation Cash Flows From Financing Activities Accounts receivable other Accounts receivable other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Entity Current Reporting Status Local Phone Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments, Due in Rolling Year Five Short-term lease cost Indianapolis, Indiana - 3 Represents the Indianapolis, Indiana - 3, during the indicated time period. Cost of goods sold Net cash (used in) operating activities Net cash (used in) operating activities Mortgage payable Changes in operating assets and liabilities Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants Represents the Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants (number of shares), during the indicated time period. Common Stock, Shares Authorized Entity Ex Transition Period Document Transition Report Stock Issuance Represents the Stock Issuance, during the indicated time period. Other Related Parties Represents the Other Related Parties, during the indicated time period. Operating expenses Cash At The Beginning Of The Period Cash At The Beginning Of The Period Cash At The End Of The Period Proceeds from the sale of common stock Property and equipment -asset purchase Property and equipment -asset purchase Accounts receivable {1} Accounts receivable Retained Earnings Gross profit (loss) Gross profit (loss) Common Stock, Shares, Outstanding Additional paid-in capital Amendment Flag Entity Small Business Entity Address, Address Line Two Stock Issued During Period, Value, Acquisitions NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Weighted average number of shares outstanding Represents the Weighted average number of shares outstanding (number of shares), during the indicated time period. Loss from continuing operations {1} Loss from continuing operations Represents the per-share monetary value of Basic and diluted earnings (loss) per common share, during the indicated time period. Other income(expense) Loss from operations Loss from operations Entity Address, State or Province Entity Address, City or Town Entity Tax Identification Number Operating lease cost Arianna Phrakornkham Represents the Arianna Phrakornkham, during the indicated time period. Revenue {1} Revenue Gross Carrying Amount Schedule of Maturities of Long-Term Debt INCOME TAXES Cash and Cash Equivalents Management's Representation of Interim Condensed Financial Statements Represents the textual narrative disclosure of Management's Representation of Interim Financial Statements Policy, during the indicated time period. Notes Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Additional Paid-in Capital Total liabilities and shareholders' deficit Total liabilities and shareholders' deficit Accounts payable and accrued expenses Entity Shell Company Entity Filer Category Stock Issuance 2 Represents the Stock Issuance 2, during the indicated time period. Operating Leases, Future Minimum Payments, Due in Rolling Year Two Operating Lease, Payments 7K Farms RE - Old National Represents the 7K Farms RE - Old National, during the indicated time period. Right of Use Asset Represents the monetary amount of Right of Use Asset, as of the indicated date. Long-Lived Tangible Asset [Axis] Segment Reporting NOTE 7 - LINE OF CREDIT Cash flows (used in) investing activities Cash flows (used in) investing activities Depreciation Condensed Consolidated Statements of Cash Flows Equity Component Condensed Consolidated Statements of Changes in Stockholders' Equity Loss from continuing operations Loss from continuing operations Loss from continuing operations Loss before provision for income taxes Loss before provision for income taxes Revenue Total shareholders' deficit Total shareholders' deficit Intangible assets Entity Emerging Growth Company Total lease cost Variable lease cost Flushing, New York Represents the Flushing, New York, during the indicated time period. Secured Debt, Current NOTE 9 - EQUITY NOTE 8 - LEASES NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Net cash provided by investing activities Net cash provided by investing activities Income (loss) from discontinued operations {1} Income (loss) from discontinued operations Represents the per-share monetary value of Basic And Diluted Earnings Loss Per Common Share From Discontinued Operations, during the indicated time period. Total operating expenses Total operating expenses Operating Expenses {1} Operating Expenses Common Stock, Shares, Issued Registrant CIK Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four Minimum Machinery and Equipment Indefinite-Lived Trademarks Goodwill, Impairment Loss Share-Based Payment Arrangement, Option, Activity Tables/Schedules Leases Goodwill and Intangible Assets NOTE 10 - COMMITMENTS AND CONTINGENCIES Net cash used in operating activities -continuing operations Net cash used in operating activities -continuing operations Net Cash Provided by (Used in) Operating Activities {1} Net Cash Provided by (Used in) Operating Activities Net Income (Loss) Net loss Rent expense Common stock, $0.0001 par value; 100,000,000 shares authorized, 77,226,355 and 70,590,898 outstanding as of September 30, 2023 and December 31 2022, respectively Total Assets Total Assets City Area Code Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due in Rolling Year Four Rome Thalop Represents the Rome Thalop, during the indicated time period. Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two Old National Loan- IN Factory Represents the Old National Loan- IN Factory, during the indicated time period. Maximum Stock Purchase Warrants Represents the textual narrative disclosure of Stock Purchase Warrants, during the indicated time period. Going Concern Policies NOTE 11 - SUBSEQUENT EVENTS NOTE 4 - DISCONTINUED OPERATIONS Notes payable related parties {1} Notes payable related parties Gain on the sale of building {1} Gain on the sale of building Stock Issued During Period, Shares, Issued for Services Common Stock, Par or Stated Value Per Share Shareholders' deficit: Accounts receivable Document Period End Date Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months Credit Facility [Axis] Gain on the sale of building Represents the monetary amount of Gain on the sale of building, during the indicated time period. Interest income Mortgage liabilities Condensed Consolidated Balance Sheets Condensed Consolidated Balance Sheets - Parenthetical Details EX-101.PRE 8 yohe-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 9 yohe-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000090 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 000440 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - NOTE 7 - LINE OF CREDIT link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies) link:presentationLink link:definitionLink link:calculationLink 000480 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000430 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - NOTE 8 - LEASES link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000490 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies) link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - NOTE 10 - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - NOTE 5 - MORTGAGES PAYABLE link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 000460 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - NOTE 9 - EQUITY link:presentationLink link:definitionLink link:calculationLink 000410 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 000450 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000540 - Disclosure - NOTE 9 - EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000420 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies) link:presentationLink link:definitionLink link:calculationLink 000510 - Disclosure - NOTE 8 - LEASES (Details) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables) link:presentationLink link:definitionLink link:calculationLink 000470 - Disclosure - NOTE 5 - MORTGAGES PAYABLE (Details) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000530 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 000500 - Disclosure - NOTE 7 - LINE OF CREDIT (Details) link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS link:presentationLink link:definitionLink link:calculationLink 000550 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink 000520 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details) link:presentationLink link:definitionLink link:calculationLink XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2023
Mar. 18, 2024
Details    
Registrant CIK 0001844793  
Fiscal Year End --12-31  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 333-222631  
Entity Registrant Name YO-HEALTH, INC.  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 85-3135038  
Entity Address, Address Line One 7551 Shelby Street  
Entity Address, Address Line Two 3rd FL  
Entity Address, City or Town Indianapolis  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46227  
City Area Code 614  
Local Phone Number 327-7630  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   77,717,721
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash $ 195,803 $ 124,062
Accounts receivable 0 179,298
Total current assets 195,803 303,361
Property plant and equipment, net 3,442,091 4,017,136
Intangible assets 40,799 37,999
Right of use assets 900,422 776,405
Other assets 6,630 1,200
Security deposits 29,150 29,150
Total Assets 4,614,894 5,165,250
Current liabilities    
Accounts payable and accrued expenses 225,944 59,233
Lease liabilities short term 204,116 188,113
Line of credit 484,490 61,490
Notes payable related parties 255,700 0
Total current liabilities 1,170,249 308,836
Long term lease liabilities 737,789 610,930
Mortgage liabilities 1,549,713 1,728,883
Total Liabilities 3,457,751 2,648,649
Shareholders' deficit:    
Common stock, $0.0001 par value; 100,000,000 shares authorized, 77,226,355 and 70,590,898 outstanding as of September 30, 2023 and December 31 2022, respectively 7,723 7,059
Additional paid-in capital 20,301,605 16,984,590
Accumulated deficit (19,152,185) (14,475,048)
Total shareholders' deficit 1,157,143 2,516,601
Total liabilities and shareholders' deficit $ 4,614,894 $ 5,165,250
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Balance Sheets - Parenthetical - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Condensed Consolidated Balance Sheets    
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 77,226,355 70,590,898
Common Stock, Shares, Outstanding 77,226,355 70,590,898
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations        
Revenue $ 2,500,311 $ 201,359 $ 5,718,680 $ 388,253
Cost of revenue 1,589,775 326,564 4,303,560 1,189,047
Gross profit (loss) 910,536 (125,204) 1,415,120 (800,793)
Operating Expenses        
General and administrative expenses 1,725,370 3,411,220 5,442,108 8,856,872
Professional fees 54,723 54,605 254,278 159,341
Rent expense 57,007 62,938 193,259 166,490
Total operating expenses 1,837,100 3,528,763 5,889,645 9,182,703
Loss from operations (926,564) (3,653,967) (4,474,525) (9,983,497)
Other income(expense)        
Interest expense (25,718) (11,290) (95,869) (34,024)
Interest income 0 1,817 0 1,817
Gain on the sale of building 0 0 438 0
Other expense, net (25,718) (9,472) (95,431) (32,207)
Loss before provision for income taxes (952,282) (3,663,439) (4,569,957) (10,015,704)
Provision (credit) for income tax 0 0 0 0
Loss from continuing operations (952,282) (3,663,439) (4,569,957) (10,015,704)
Income (loss) from discontinued operations 0 9,047 (107,180) 208,938
Net loss $ (952,282) $ (3,654,392) $ (4,677,137) $ (9,806,766)
Loss from continuing operations $ (0.01) $ (0.05) $ (0.06) $ (0.16)
Income (loss) from discontinued operations $ 0 $ 0.00 $ (0.00) $ 0.00
Weighted average number of shares outstanding 76,661,355 67,338,998 75,054,536 62,272,998
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Retained Earnings
Total
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2021 $ 5,123 $ 7,159,526 $ (3,593,926) $ 3,570,723
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 51,232,998      
Stock Issued During Period, Value, Issued for Services $ 1 4,999   5,000
Stock Issued During Period, Shares, Issued for Services 10,000      
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 90 505,110   505,200
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 898,000      
Net Income (Loss)     (520,868) (520,868)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2022 $ 5,214 7,669,635 (4,114,794) 3,560,055
Shares, Outstanding, Ending Balance at Mar. 31, 2022 52,140,998      
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2021 $ 5,123 7,159,526 (3,593,926) 3,570,723
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 51,232,998      
Net Income (Loss)       (9,806,766)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2022 $ 7,043 16,903,106 (13,400,692) 3,509,457
Shares, Outstanding, Ending Balance at Sep. 30, 2022 70,427,998      
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2022 $ 5,214 7,669,635 (4,114,794) 3,560,055
Shares, Outstanding, Beginning Balance at Mar. 31, 2022 52,140,998      
Stock Issued During Period, Value, Issued for Services $ 1,024 5,119,226   5,120,250
Stock Issued During Period, Shares, Issued for Services 10,240,500      
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 187 1,019,613   1,019,800
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 1,868,500      
Net Income (Loss)     (5,631,505) (5,631,505)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2022 $ 6,425 13,808,474 (9,746,299) 4,068,600
Shares, Outstanding, Ending Balance at Jun. 30, 2022 64,249,998      
Stock Issued During Period, Value, Issued for Services $ 611 3,059,639   3,060,250
Stock Issued During Period, Shares, Issued for Services 6,108,000      
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 7 34,993   35,000
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 70,000      
Net Income (Loss)     (3,654,392) (3,654,392)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2022 $ 7,043 16,903,106 (13,400,692) 3,509,457
Shares, Outstanding, Ending Balance at Sep. 30, 2022 70,427,998      
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022 $ 7,059 16,984,590 (14,475,048) 2,516,601
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 70,590,898      
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 14 69,985   70,000
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 140,000      
Net Income (Loss)     (837,652) (837,652)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2023 $ 7,184 17,609,464 (15,312,700) 2,303,949
Shares, Outstanding, Ending Balance at Mar. 31, 2023 71,840,898      
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture $ 111 554,889   555,000
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture 1,110,000      
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022 $ 7,059 16,984,590 (14,475,048) 2,516,601
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 70,590,898      
Stock Issued During Period, Value, Issued for Services       3,187,679
Stock Issued During Period, Shares, Issued for Services 6,375,357      
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants       130,000
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 260,000      
Net Income (Loss)       (4,677,137)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2023 $ 7,723 20,301,605 (19,152,185) 1,157,143
Shares, Outstanding, Ending Balance at Sep. 30, 2023 77,226,355      
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2023 $ 7,184 17,609,464 (15,312,700) 2,303,949
Shares, Outstanding, Beginning Balance at Mar. 31, 2023 71,840,898      
Net Income (Loss)     (2,887,203) (2,887,203)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2023 $ 7,610 19,736,718 (18,199,903) 1,544,424
Shares, Outstanding, Ending Balance at Jun. 30, 2023 76,096,355      
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture $ 426 2,127,254   2,127,680
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture 4,255,457      
Net Income (Loss)     (952,282) (952,282)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2023 $ 7,723 20,301,605 $ (19,152,185) 1,157,143
Shares, Outstanding, Ending Balance at Sep. 30, 2023 77,226,355      
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture $ 113 $ 564,887   $ 565,000
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture 1,130,000      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Net Cash Provided by (Used in) Operating Activities    
Loss from continuing operations $ (4,569,957) $ (10,015,704)
Less: income (loss) from discontinued operations (107,180) 208,938
Net loss (4,677,137) (9,806,766)
Stock based compensation 3,247,680 8,185,500
Depreciation 232,222 34,971
Gain on the sale of building (438)  
Changes in operating assets and liabilities    
Accounts receivable 179,298 110,678
Accounts receivable other 0 7,400
Subscriptions receivable 0 20,000
Other assets (5,430) 0
Security deposits 0 (6,700)
Accounts payable and accrued liabilities 175,305 50,926
Mortgage payable (34,171) 106,611
Net cash used in operating activities -continuing operations (882,670) (1,297,380)
Net cash provided by (used in) operating activities -discontinued operations 0 0
Net cash (used in) operating activities (882,670) (1,297,380)
Cash flows from Investing Activities    
Property and equipment -asset purchase (49,289) (410,312)
Cash flows (used in) investing activities (49,289) (410,312)
Cash Flows From Financing Activities    
Proceeds from line of credit 423,000 0
Notes payable related parties 255,700 0
Proceeds from the sale of property 255,000 0
Proceeds from the sale of common stock 70,000 1,560,000
Net cash provided by investing activities 1,003,700 1,560,000
Net Increase (Decrease) In Cash 71,741 (147,692)
Cash At The Beginning Of The Period 124,062 1,429,587
Cash At The End Of The Period $ 195,803 $ 1,281,895
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Nature of Operations

 

YO-Health, Inc. (“YO-Health” or the “Company”) was established as a C-Corporation in Nevada on October 22, 2020. The Company is the parent company to Yoshi Inc, Sun & Moon Café, 7K Farms and Joyce’s Bakery Inc. YO-Health manufactures, retails, wholesales, and distributes premium, healthy, unique, and innovative food products.

 

The Company commenced operations in October 2020 by acquiring a Beijing-style premium yogurt store in Woodside, New York. The Company has since launched the subsidiaries Yoshi Restaurants, Inc., Sun & Moon, and Joyce’s Bakery & Café, Inc.

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc.

 

The Company currently has 4 Yoshi model restaurants, 1 Sun & Moon Café and 1 yogurt manufacturing facility.

 

Each subsidiary company of YO-Health, Inc. will focus on their respective products on a wholesale and retail basis:

 

Sun & Moon will produce, market, and sell yogurt-based items with probiotics and ingredients focused on beneficial healthy products.

 

Yoshi will produce, market, and sell Asian fusion food products.

 

Joyce’s Bakery & Café will produce, market, and sell premium, Asian- French-inspired desserts, Tea’s, Juices, and flavored coffee with a full array of non-alcoholic drinks.

 

7K Farms delivers wholesale food and supplies to the Company locations as well as other restaurant and grocery locations.

 

On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation -see Note 4. Discontinued Operations.

 

The Company’s accounting year-end is December 31.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The condensed consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Yoshi Inc, Sun & Moon Café, and Joyce’s Bakery Inc.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed consolidated financial statements.

 

For the nine months ended September 30, 2023, the Company had a loss from continuing operations of $4,569,957. As of September 30, 2023 the Company had an accumulated deficit of $19,152,185. The Company expects to generate operating cash flows that will be sufficient to fund presently anticipated operations although there can be no assurance. This raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing to supplement the expected cash flow.

 

Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its revenues support its operations.

 

The Company may attempt to raise capital in the near future through the sale of equity or debt financing; however, there can be assurances the Company will be successful in doing so. There can be no assurance that such additional financing will be available to the Company on acceptable terms or at all.

 

Management’s Representation of Interim Condensed Consolidated Financial Statements

 

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual condensed financial statements. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed financial statements include all of the adjustments, which in the opinion of management are necessary for a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of goodwill, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable, and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Segment Reporting

 

The Company operates in one segment, the food service business. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying condensed consolidated financial statements.

 

Goodwill and Intangible Assets

 

Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter.

 

Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill and indefinite-lived assets during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry, and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.

 

Indefinite-lived intangible assets are evaluated for impairment at the individual asset level by assessing whether it is more likely than not that the asset is impaired (for example, that the fair value of the asset is below its carrying amount). If it is more likely than not that the asset is impaired, its carrying amount is written down to its fair value.

 

Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.

 

We performed our annual fair value assessment on December 31, 2021, on our purchases of the New Orleans, Woodside, 7K Farms and the Champagne, Illinois acquisitions, and determined that an impairment charge of $750,000 and $1,000,000, respectively, was necessary for the years ended December 31, 2022, and 2021. As a result, we had no goodwill as of September 30, 2023, and December 31, 2022, respectively. The balance of indefinite-lived intangible assets comprised of trademarks were $40,799 and $37,399, respectively, as of September 30, 2023, and December 31, 2022.

 

Revenue Recognition

 

The Company recognizes revenue under the guidelines of ASC 606. Sales, as presented in the Company’s statement of earnings, represent revenue; and food and beverage products sold which is presented net of discounts, coupons, employee meals and complimentary meals. Revenue is recognized using the five step approach required under the guidelines of ASC 606:

 

1.Identify the contract with the client, 

 

2.Identify the performance obligations in the contract, 

 

3.Determine the transaction price, 

 

4.Allocate the transaction price to performance obligations in the contract 

 

5.Recognize revenues when or as the Company satisfies a performance obligation 

 

For retail operations, all five steps of revenue recognition occur almost simultaneously. The customer orders food from a menu or store sign, it is given to the customer who then pays for the food order at the cash register. The Company’s store business represented approximately 27.6% and 100% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

 

For wholesale sales the customer orders wholesale items from a store sign or catalogue, it is given or delivered to the customer who then pays for the items within 7 days of sale. The Company’s store business represented approximately 72.4% and 0% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On September 30, 2023, and December 31, 2022, the Company’s cash equivalents totaled $195,803 and $124,062 , respectively.

 

Property and equipment

 

Property and equipment are stated at cost or fair value. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expenses as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in the results of operations. The estimated useful lives of property and equipment are as follows:

 

Computers, software, and office equipment

1 – 6 years

Machinery and equipment

3 – 5 years

Leasehold improvements

Lesser of lease term or estimated useful life

Buildings

39 years

 

Equipment that hasn’t been placed into service is not subject to depreciation.

 

Depreciation expense for the nine months ended September 30, 2023 and 2022 was $232,222 and $23,314, respectively.

 

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

 

Leases

The Company currently follows the guidance in ASC 840 “Leases,” which requires us to evaluate the lease agreements the Company enters into to determine whether they represent operating or capital leases at the inception of the lease.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), that requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The accounting treatment for finance leases and lessors remains relatively unchanged. The accounting standards update also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB approved an amendment to the new guidance that introduced an alternative modified retrospective transition approach granting companies the option of using the effective date of the new standard as the date of initial application. The Company adopted the standard using the effective date method on December 31, 2022.

The Company elected the transition package of practical expedients that is permitted by the standard. The package of practical expedients allows the Company to not reassess previous accounting conclusions regarding whether existing arrangements are or contain leases, the classification of existing leases, and the treatment of initial direct costs. The Company did not elect the hindsight transition practical expedient allowed for by the new standard, which allows entities to use hindsight when determining lease term and impairment of ROU assets. Additionally, the Company elected certain other practical expedients offered by the new standard which it will apply to all asset classes, including the option not to separate lease and non-lease components and instead to account for them as a single lease component and the option not to recognize ROU assets and related liabilities that arise from short-term leases (i.e., leases with terms of twelve months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise).

The standard had a material impact on the balance sheet on the date of adoption, with the most significant impact being the recognition of $900,422 operating lease right-of-use assets and $204,116 operating lease liabilities.

 

As part of its adoption of the new lease accounting standard, the Company also implemented new internal controls and updated accounting policies and procedures, operational processes and documentation practices to enable the preparation of financial information on adoption. Refer to Note 6: Leases - Accounting Principles and Leases for additional disclosures required as a result of the adoption of this new standard.

 

Stock Purchase Warrants

 

The Company has issued warrants to purchase shares of its common stock. Warrants have been accounted for as equity in accordance with FASB ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the

enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

On Dec. 18, 2019, the Financial Accounting Standards Board (FASB) released Accounting Standards Update (ASU) 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The FASB has stated that the ASU is being issued as part of its Simplification Initiative, which is meant to reduce complexity in accounting standards by improving certain areas of generally accepted accounting principles (GAAP) without compromising information provided to users of condensed consolidated financial statements. The Company adopted this guidance on January 1, 2021, which had no impact on the Company’s condensed consolidated financial statements.

 

Net Loss per Share

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, "Earnings per Share." Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and diluted common share equivalents outstanding.

 

Discontinued Operations

 

The operations of the Company’s former Winn Sushi Division has been presented as discontinued operations. Unless otherwise noted, amounts and disclosures throughout these Notes to Condensed Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 4. for additional information on discontinued operations.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard. On November 15, 2019, the FASB has issued ASU 2019-10, which amends the effective dates for three major accounting standards. The ASU defers the effective dates for the credit losses, derivatives, and lease standards for certain companies.   The Company adopted ASC 842 on December 31, 2022.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT

NOTE 3 – PROPERTY, PLANT, AND EQUIPMENT

 

The following table sets forth the components of the Company’s property and equipment on September 30, 2023, and December 31, 2022:

 

 

 

September 30, 2023

 

 

December 31, 2022

 

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

Computers, software, property, and equipment

 

 

$3,761,670 

 

 

 

$(469,579) 

 

 

 

$3,292,091 

 

 

 

$4,060,518 

 

 

 

$(242,382) 

 

 

 

$3,818,136 

 

Land

 

 

150,000 

 

 

 

 

 

 

 

150,000 

 

 

 

199,000 

 

 

 

 

 

 

 

199,000 

 

Total fixed assets

 

 

$3,911,670 

 

 

 

$(469,579) 

 

 

 

$3,442,091 

 

 

 

$4,259,518 

 

 

 

$(242,382) 

 

 

 

$4,017,136 

 

 

On September 21, 2021 the Company entered into an Exchange Agreement with Yoshi Properties, LLC, an Ohio limited liability company and its sole members, Peter and Vila Thawnghmung who are both officers and directors of the Company, and related parties. Under the terms of the Exchange Agreement the Company purchased ownership of all of the membership interests (100%) in Yoshi Properties, comprised solely of two properties and the related mortgages for consideration of 1,000,000 shares of the Company’s common stock. No other assets or liabilities were included in the purchase price.

 

The fair market value of the properties acquired from Yoshi Properties, LLC was estimated to be equivalent to the mortgages assumed, or approximately $695,000. The 1,000,000 shares issued to Yoshi Properties was recorded at a value of $0.50 per share which was equivalent to the price of $0.50 per share paid by investors in the Company’s private placement offering of common stock at that time. As a result the Company recorded $500,000 in stock-based compensation expenses on its Statements of Operations for the year ended December 31, 2021.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 4 - DISCONTINUED OPERATIONS
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 4 - DISCONTINUED OPERATIONS

NOTE 4 – DISCONTINUED OPERATIONS

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation.

 

The components of the loss from discontinued operations for the three and nine months ended September 30, 2023, and 2022 in the statement of operations consisted of the following:

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

2023

 

2022

 

2023

 

2022

Revenue

$- 

 

$746,462 

 

$866,247  

 

$2,069,135 

Cost of goods sold

- 

 

715,906 

 

798,911  

 

1,834,625 

Gross Profit

- 

 

30,556 

 

67,336  

 

234,510 

Operating expenses

- 

 

21,509 

 

174,516  

 

25,572 

Discontinued operations, net of tax

$- 

 

$9,047 

 

$(107,180) 

 

$208,938 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 5 - MORTGAGES PAYABLE
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 5 - MORTGAGES PAYABLE

NOTE 5 – MORTGAGES PAYABLE

 

The balance in mortgages payable was $1,549,713 and $1,728,883 as of September 30, 2023, and December 31, 2022, respectively. The mortgage balance as of September 30, 2023, is comprised of:

 

·Mortgage Loans: CNB Bank- OH Store = $ 270,466 

·Mortgage Loans: Old National Bank- LA Store/Fac = $ 525,380 

·Mortgage Loans: Old National Loan- IN Factory = $ 260,240 

·Mortgage Loans: Old National – 7K farms - Mtg = $ 493,627 

 

Interest expense on these mortgages were $66,522 and $34,024, for the nine months ended September 30, 2023, and September 30, 2022, respectively. The interest expense balance as of September 30, 2023, is comprised of:

 

·Interest Expense: OH Store- CNB Bank = $ 15,647 

oInterest Rate: 7.34% 

·Interest Expense: LA Store/Factory- Old National = $ 16,239 

oInterest Rate: 4% 

·Interest Expense: IN Factory- Old National = $ 8,046 

oInterest Rate: 4% 

·Interest Expense: 7K Farms RE - Old National = $ 26,590 

oInterest Rate: 6.5% 

 

On September 30, 2023, the aggregate maturities of notes payable for the next five years and thereafter are as follows:

 

2022

 

$

 -

2023

 

 -

2024

 

$

 -

2025

 

$

 -

2026 and thereafter

 

$

1,549,713 

Total

 

$

1,549,713 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 6 - RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 6 - RELATED PARTY TRANSACTIONS

NOTE 6 – RELATED PARTY TRANSACTIONS

 

Peter Thawnghmung, the Company’s Chairman and CEO is the spouse of Vila Thawnghmung, who is a director of the Company. The Company has 4 directors, therefore, Peter and Vila Thawnghmung, two of those directors can control all Company activity. Peter and Vila Thawnghmung have personally guaranteed all of the mortgages on the real properties owned by the Company and its subsidiaries as well as the Line of Credit. Arianna Phrakornkham, their daughter, is the controller of the Company.

 

In 2021 Peter and Vila Thawnghmung received 1,048,000 common shares for services performed. These shares were valued at $524,000. Related parties to Peter and Vila Thawnghmung received 120,000 common shares for services valued at $60,000.

 

In 2022 Peter and Vila Thawnghmung received 9,051,000 common shares for services performed. These shares were valued at $4,525,500. Arianna Phrakornkham received 1,000,000 shares valued at $500,000 for services. Related parties to Peter and Vila Thawnghmung received 1,127,000 common shares valued at $63,500.

 

During the nine months ended September 30, 2023, Peter and Vila Thawnghmung received 68,000 shares for service performed. These share were valued at $34,000. During this period, Rome Thalop, who was appointed a director on March 23, 2023, received 16,000 shares valued at $8,000 for his ongoing services as a director.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 7 - LINE OF CREDIT
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 7 - LINE OF CREDIT

NOTE 7 – LINE OF CREDIT

 

As of September 30, 2023, the Company has one line of credit with Old National Bank. The interest rate is 8.75% with a credit limit of $500,00 and a loan term of 24 months. The loan originated on 10/31/2022 and expires on 10/31/2024. The line of credit is collateralized by 7K Farms and was personally guaranteed by Peter and Vila Thawnghmung. The balance of the line of credit was $484,900 and $61,490 as of September 30, 2023 and September 30, 2022, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 8 - LEASES

NOTE 8 – LEASES

 

As of September 30, 2023, the Company had signed 6 long-term leases:

 

·Flushing, New York: The Company entered into a lease for $7,500/month with a lease term of 5 years (11/25/2020 – 11/15/2025). 

·Columbus, Ohio: The Company entered into a lease for $3,370.83/month with a lease term of 7 years (6/4/2021 – 3/31/2028). 

·Indianapolis, Indiana: The Company entered into a lease for $3,065.75/month with a lease term of 5 years (5/1/2021 – 4/30/2026). 

·Indianapolis, Indiana: The Company entered into a lease for $4,200/month with a lease term of 6 years (6/1/2022 – 5/31/2028). 

·Indianapolis, Indiana: The Company entered into a lease for $4,911.83/month with a lease term of 5 years (5/1/2023 – 10/31/2028). 

·Columbus, Ohio: The Company entered into a lease for $3,798/month with a lease term of 5.6 years (9/1/2023 – 4/31/2029). 

 

Accounting Principles

 

Under ASC 842, the determination of whether an arrangement is a lease is made at the lease’s inception and a contract is (or contains) a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is defined under the standard as having both the right to obtain substantially all of the economic benefits from use of the asset and the right to direct the use of the asset. Management only reassesses its determination if the terms and conditions of the contract are changed. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our balance sheets.

 

ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when it is readily determinable. Since most of the Company’s leases do not provide an implicit rate, to determine the present value of lease payments, management uses the Company’s incremental borrowing rate based on the information available at lease commencement. Operating lease ROU assets also include any lease payments made and exclude any lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option, with renewal options that can extend the lease from three to five years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.

 

The Company has lease agreements with lease and non-lease components, for which it has made an accounting policy election to account for these as a single lease component.

Leases

 

The Company leases retail spaces under operating lease agreements that have term lengths of five to seven years and that have renewal options that range from three to five years. The Company pays certain variable lease costs such as real estate taxes, insurance, and common area maintenance charges. The Company accounts for lease and non-lease components as a single lease component.

 

 

Lease Cost

 

 

 

 

 

Operating lease cost

 

220,622

 

Short-term lease cost

 

 

3,854

 

Variable lease cost

 

 

27,166

 

Total lease cost

 

$

251,642

 

 

The weighted average remaining lease term for operating leases is 3.73 years and the weighted average discount rate for operating leases is 4%.

 

Maturities of lease liabilities as of September 30, 2023, were as follows:

 

 

 

Operating

 

 

 

Leases

 

2023

 

$

 

2024

 

 

212,833

 

2025

 

 

208,660

 

2026

 

 

103,114

 

2027

 

 

95,650

 

Thereafter

 

 

33,112

 

 

 

 

809,679

 

Less imputed interest

 

 

70,124

 

Total

 

$

739,555

 

 

Operating cash flows from operating leases for the year ended December 31, 2022, was $197,187, and lease assets were obtained in exchange for operating lease liabilities for the year ended December 31, 2022, of $693,230.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 9 - EQUITY
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 9 - EQUITY

NOTE 9 – EQUITY

 

The Company has authorized 100,000,000 shares of par value of $0.0001 common stock. As of September 30, 2023, and December 31, 2022, the Company had 77,226,355 and 70,590,898 common shares issued and outstanding, respectively.

 

September 30, 2023 Activity

 

During the nine months ended September 30, 2023, the Company had the following common stock transactions:

 

·Issuance of 6,375,357 shares for services valued at $3,187679. 

 

·Issuance of 260,000 shares in private placements valued at $130,000. 

 

December 31, 2022 Activity

 

During the year ended December 31, 2022, the Company had the following common stock transactions:

 

·Issuance of 2,773,900 shares in private placements valued at $1,534,999. 

 

·Issuance of 15,584,000 shares for services valued at $7,792,000. 

 

·Issuance of 1,000,000 shares for the purchase of 7K Farms valued at $500,000. 

 

Warrants

 

As of September 30, 2023, the Company had 6,059,998 warrants outstanding, all with a strike price of $1.25. The warrants have a two-year term and expire at varying times between September 30, 2023 and June 13, 2025.

 

A summary of the status of the outstanding stock warrants is presented below:

 

Exercise Price

 

 

Number Outstanding

9/30/2023

 

 

Weighted Average

Remaining Contractual Life

 

 

Weighted Average

Exercise Price

$1.25

 

 

6,059,998

 

 

0.39 years

 

 

$1.25

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 10 - COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 10 - COMMITMENTS AND CONTINGENCIES

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

Legal Proceedings

 

On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 11 - SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2023
Notes  
NOTE 11 - SUBSEQUENT EVENTS

NOTE 11 – SUBSEQUENT EVENTS

 

As of September 30, 2023, the Company had 77,226,355 shares of its common stock issued and outstanding. Subsequent to September 30, 2023, the Company had 77,717,721 shares of its common stock issued and outstanding. From October 1, 2023 – March 5, 2024, an additional 491,366 shares were issued, 431,366 shares were for services.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Basis of Presentation

Basis of Presentation

 

The condensed consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Yoshi Inc, Sun & Moon Café, and Joyce’s Bakery Inc.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Going Concern

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed consolidated financial statements.

 

For the nine months ended September 30, 2023, the Company had a loss from continuing operations of $4,569,957. As of September 30, 2023 the Company had an accumulated deficit of $19,152,185. The Company expects to generate operating cash flows that will be sufficient to fund presently anticipated operations although there can be no assurance. This raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing to supplement the expected cash flow.

 

Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its revenues support its operations.

 

The Company may attempt to raise capital in the near future through the sale of equity or debt financing; however, there can be assurances the Company will be successful in doing so. There can be no assurance that such additional financing will be available to the Company on acceptable terms or at all.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Management's Representation of Interim Condensed Financial Statements

Management’s Representation of Interim Condensed Consolidated Financial Statements

 

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual condensed financial statements. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed financial statements include all of the adjustments, which in the opinion of management are necessary for a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Use of Estimates

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of goodwill, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable, and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Segment Reporting

Segment Reporting

 

The Company operates in one segment, the food service business. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying condensed consolidated financial statements.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter.

 

Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill and indefinite-lived assets during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry, and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.

 

Indefinite-lived intangible assets are evaluated for impairment at the individual asset level by assessing whether it is more likely than not that the asset is impaired (for example, that the fair value of the asset is below its carrying amount). If it is more likely than not that the asset is impaired, its carrying amount is written down to its fair value.

 

Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.

 

We performed our annual fair value assessment on December 31, 2021, on our purchases of the New Orleans, Woodside, 7K Farms and the Champagne, Illinois acquisitions, and determined that an impairment charge of $750,000 and $1,000,000, respectively, was necessary for the years ended December 31, 2022, and 2021. As a result, we had no goodwill as of September 30, 2023, and December 31, 2022, respectively. The balance of indefinite-lived intangible assets comprised of trademarks were $40,799 and $37,399, respectively, as of September 30, 2023, and December 31, 2022.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue under the guidelines of ASC 606. Sales, as presented in the Company’s statement of earnings, represent revenue; and food and beverage products sold which is presented net of discounts, coupons, employee meals and complimentary meals. Revenue is recognized using the five step approach required under the guidelines of ASC 606:

 

1.Identify the contract with the client, 

 

2.Identify the performance obligations in the contract, 

 

3.Determine the transaction price, 

 

4.Allocate the transaction price to performance obligations in the contract 

 

5.Recognize revenues when or as the Company satisfies a performance obligation 

 

For retail operations, all five steps of revenue recognition occur almost simultaneously. The customer orders food from a menu or store sign, it is given to the customer who then pays for the food order at the cash register. The Company’s store business represented approximately 27.6% and 100% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

 

For wholesale sales the customer orders wholesale items from a store sign or catalogue, it is given or delivered to the customer who then pays for the items within 7 days of sale. The Company’s store business represented approximately 72.4% and 0% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On September 30, 2023, and December 31, 2022, the Company’s cash equivalents totaled $195,803 and $124,062 , respectively.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Property and Equipment

Property and equipment

 

Property and equipment are stated at cost or fair value. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expenses as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in the results of operations. The estimated useful lives of property and equipment are as follows:

 

Computers, software, and office equipment

1 – 6 years

Machinery and equipment

3 – 5 years

Leasehold improvements

Lesser of lease term or estimated useful life

Buildings

39 years

 

Equipment that hasn’t been placed into service is not subject to depreciation.

 

Depreciation expense for the nine months ended September 30, 2023 and 2022 was $232,222 and $23,314, respectively.

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Stock-based Compensation

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Leases

Leases

The Company currently follows the guidance in ASC 840 “Leases,” which requires us to evaluate the lease agreements the Company enters into to determine whether they represent operating or capital leases at the inception of the lease.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), that requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The accounting treatment for finance leases and lessors remains relatively unchanged. The accounting standards update also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB approved an amendment to the new guidance that introduced an alternative modified retrospective transition approach granting companies the option of using the effective date of the new standard as the date of initial application. The Company adopted the standard using the effective date method on December 31, 2022.

The Company elected the transition package of practical expedients that is permitted by the standard. The package of practical expedients allows the Company to not reassess previous accounting conclusions regarding whether existing arrangements are or contain leases, the classification of existing leases, and the treatment of initial direct costs. The Company did not elect the hindsight transition practical expedient allowed for by the new standard, which allows entities to use hindsight when determining lease term and impairment of ROU assets. Additionally, the Company elected certain other practical expedients offered by the new standard which it will apply to all asset classes, including the option not to separate lease and non-lease components and instead to account for them as a single lease component and the option not to recognize ROU assets and related liabilities that arise from short-term leases (i.e., leases with terms of twelve months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise).

The standard had a material impact on the balance sheet on the date of adoption, with the most significant impact being the recognition of $900,422 operating lease right-of-use assets and $204,116 operating lease liabilities.

 

As part of its adoption of the new lease accounting standard, the Company also implemented new internal controls and updated accounting policies and procedures, operational processes and documentation practices to enable the preparation of financial information on adoption. Refer to Note 6: Leases - Accounting Principles and Leases for additional disclosures required as a result of the adoption of this new standard.

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Stock Purchase Warrants

Stock Purchase Warrants

 

The Company has issued warrants to purchase shares of its common stock. Warrants have been accounted for as equity in accordance with FASB ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
INCOME TAXES

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the

enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

On Dec. 18, 2019, the Financial Accounting Standards Board (FASB) released Accounting Standards Update (ASU) 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The FASB has stated that the ASU is being issued as part of its Simplification Initiative, which is meant to reduce complexity in accounting standards by improving certain areas of generally accepted accounting principles (GAAP) without compromising information provided to users of condensed consolidated financial statements. The Company adopted this guidance on January 1, 2021, which had no impact on the Company’s condensed consolidated financial statements.

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Net Loss Per Share

Net Loss per Share

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, "Earnings per Share." Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and diluted common share equivalents outstanding.

 

Discontinued Operations

 

The operations of the Company’s former Winn Sushi Division has been presented as discontinued operations. Unless otherwise noted, amounts and disclosures throughout these Notes to Condensed Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 4. for additional information on discontinued operations.

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)
9 Months Ended
Sep. 30, 2023
Policies  
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard. On November 15, 2019, the FASB has issued ASU 2019-10, which amends the effective dates for three major accounting standards. The ASU defers the effective dates for the credit losses, derivatives, and lease standards for certain companies.   The Company adopted ASC 842 on December 31, 2022.

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Property, Plant and Equipment

 

 

 

September 30, 2023

 

 

December 31, 2022

 

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

 

Gross Carrying Amount

 

 

Accumulated Depreciation

 

 

Net Book Value

 

Computers, software, property, and equipment

 

 

$3,761,670 

 

 

 

$(469,579) 

 

 

 

$3,292,091 

 

 

 

$4,060,518 

 

 

 

$(242,382) 

 

 

 

$3,818,136 

 

Land

 

 

150,000 

 

 

 

 

 

 

 

150,000 

 

 

 

199,000 

 

 

 

 

 

 

 

199,000 

 

Total fixed assets

 

 

$3,911,670 

 

 

 

$(469,579) 

 

 

 

$3,442,091 

 

 

 

$4,259,518 

 

 

 

$(242,382) 

 

 

 

$4,017,136 

 

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Disposal Groups, Including Discontinued Operations

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

2023

 

2022

 

2023

 

2022

Revenue

$- 

 

$746,462 

 

$866,247  

 

$2,069,135 

Cost of goods sold

- 

 

715,906 

 

798,911  

 

1,834,625 

Gross Profit

- 

 

30,556 

 

67,336  

 

234,510 

Operating expenses

- 

 

21,509 

 

174,516  

 

25,572 

Discontinued operations, net of tax

$- 

 

$9,047 

 

$(107,180) 

 

$208,938 

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Schedule of Maturities of Long-Term Debt

 

2022

 

$

 -

2023

 

 -

2024

 

$

 -

2025

 

$

 -

2026 and thereafter

 

$

1,549,713 

Total

 

$

1,549,713 

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Schedule of lease costs and other information relating to the Company's operating leases

 

Lease Cost

 

 

 

 

 

Operating lease cost

 

220,622

 

Short-term lease cost

 

 

3,854

 

Variable lease cost

 

 

27,166

 

Total lease cost

 

$

251,642

 

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Schedule of Maturities of Lease Liabilities

 

 

 

Operating

 

 

 

Leases

 

2023

 

$

 

2024

 

 

212,833

 

2025

 

 

208,660

 

2026

 

 

103,114

 

2027

 

 

95,650

 

Thereafter

 

 

33,112

 

 

 

 

809,679

 

Less imputed interest

 

 

70,124

 

Total

 

$

739,555

 

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables)
9 Months Ended
Sep. 30, 2023
Tables/Schedules  
Share-Based Payment Arrangement, Option, Activity

 

Exercise Price

 

 

Number Outstanding

9/30/2023

 

 

Weighted Average

Remaining Contractual Life

 

 

Weighted Average

Exercise Price

$1.25

 

 

6,059,998

 

 

0.39 years

 

 

$1.25

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)
9 Months Ended
Sep. 30, 2023
Details  
Entity Incorporation State Country Name Nevada
Entity Incorporation, Date of Incorporation Oct. 22, 2020
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Details          
Loss from continuing operations $ 952,282 $ 3,663,439 $ 4,569,957 $ 10,015,704  
Accumulated deficit $ 19,152,185   $ 19,152,185   $ 14,475,048
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2023
Details      
Goodwill, Impairment Loss $ 750,000 $ 1,000,000  
Indefinite-Lived Trademarks $ 37,399   $ 40,799
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Details      
Cash $ 195,803 $ 124,062 $ 124,062
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Depreciation Expense on Reclassified Assets $ 232,222 $ 23,314
Computer Equipment | Minimum    
Property, Plant and Equipment, Useful Life 1 year  
Computer Equipment | Maximum    
Property, Plant and Equipment, Useful Life 6 years  
Machinery and Equipment | Minimum    
Property, Plant and Equipment, Useful Life 3 years  
Machinery and Equipment | Maximum    
Property, Plant and Equipment, Useful Life 5 years  
Building    
Property, Plant and Equipment, Useful Life 39 years  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Details    
Right of Use Asset $ 900,422  
Lease liabilities short term $ 204,116 $ 188,113
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Computer Equipment    
Gross Carrying Amount $ 3,761,670 $ 4,060,518
Accumulated Depreciation (469,579) (242,382)
Property plant and equipment, net 3,292,091 3,818,136
Land    
Gross Carrying Amount 150,000 199,000
Accumulated Depreciation 0 0
Property plant and equipment, net 150,000 199,000
Gross Carrying Amount 3,911,670 4,259,518
Accumulated Depreciation (469,579) (242,382)
Property plant and equipment, net $ 3,442,091 $ 4,017,136
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Details        
Revenue $ 0 $ 746,462 $ 866,247 $ 2,069,135
Cost of goods sold 0 715,906 798,911 1,834,625
Gross Profit 0 30,556 67,336 234,510
Operating expenses 0 21,509 174,516 25,572
Income (loss) from discontinued operations $ 0 $ 9,047 $ (107,180) $ 208,938
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 5 - MORTGAGES PAYABLE (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Mortgage liabilities $ 1,549,713   $ 1,549,713   $ 1,728,883
Secured Debt, Current 1,549,713   1,549,713    
Interest Expense 25,718 $ 11,290 95,869 $ 34,024  
CNB Bank- OH Store          
Secured Debt, Current 270,466   270,466    
Interest Expense     15,647    
Old National Bank- LA Store/Fac          
Secured Debt, Current 525,380   525,380    
Interest Expense     8,046    
Old National Loan- IN Factory          
Secured Debt, Current 260,240   260,240    
Interest Expense     16,239    
Old National - 7K farms - Factory          
Secured Debt, Current $ 493,627   493,627    
7K Farms RE - Old National          
Interest Expense     $ 26,590    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details)
Sep. 30, 2023
USD ($)
Details  
Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months $ 0
Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two 0
Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three 0
Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four 0
Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five 1,549,713
Secured Debt, Current $ 1,549,713
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 6 - RELATED PARTY TRANSACTIONS (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Stock Issued During Period, Value, Issued for Services $ 3,060,250 $ 5,120,250 $ 5,000 $ 3,187,679    
Peter and Vila Thawnghmung            
Stock Issued During Period, Value, Issued for Services       34,000 $ 4,525,500 $ 524,000
Other Related Parties            
Stock Issued During Period, Value, Issued for Services         63,500 $ 60,000
Arianna Phrakornkham            
Stock Issued During Period, Value, Issued for Services         $ 500,000  
Rome Thalop            
Stock Issued During Period, Value, Issued for Services       $ 8,000    
Common Stock            
Stock Issued During Period, Shares, Issued for Services 6,108,000 10,240,500 10,000 6,375,357    
Stock Issued During Period, Value, Issued for Services $ 611 $ 1,024 $ 1      
Common Stock | Peter and Vila Thawnghmung            
Stock Issued During Period, Shares, Issued for Services       68,000 9,051,000 1,048,000
Common Stock | Other Related Parties            
Stock Issued During Period, Shares, Issued for Services         1,127,000 120,000
Common Stock | Arianna Phrakornkham            
Stock Issued During Period, Shares, Issued for Services         1,000,000  
Common Stock | Rome Thalop            
Stock Issued During Period, Shares, Issued for Services       16,000    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 7 - LINE OF CREDIT (Details)
9 Months Ended
Sep. 30, 2023
Details  
Debt Instrument, Description the Company has one line of credit with Old National Bank. The interest rate is 8.75% with a credit limit of $500,00 and a loan term of 24 months. The loan originated on 10/31/2022 and expires on 10/31/2024. The line of credit is collateralized by 7K Farms and was personally guaranteed by Peter and Vila Thawnghmung. The balance of the line of credit was $484,900 and $61,490 as of September 30, 2023 and September 30, 2022, respectively
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Operating cash flows from operating leases   $ 197,187
Operating Lease, Liability   $ 693,230
Flushing, New York    
Operating Lease, Payments $ 7,500  
Columbus, Ohio    
Operating Lease, Payments 3,370  
Indianapolis, Indiana - 1    
Operating Lease, Payments 3,065  
Indianapolis, Indiana - 2    
Operating Lease, Payments 4,200  
Indianapolis, Indiana - 3    
Operating Lease, Payments 4,911  
Columbus, Ohio - 2    
Operating Lease, Payments $ 3,798  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details)
9 Months Ended
Sep. 30, 2023
USD ($)
Details  
Operating lease cost $ 220,622
Short-term lease cost 3,854
Variable lease cost 27,166
Total lease cost $ 251,642
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details)
9 Months Ended
Sep. 30, 2023
USD ($)
Details  
Operating Leases, Future Minimum Payments, Due in Rolling Year Two $ 212,833
Operating Leases, Future Minimum Payments, Due in Rolling Year Three 208,660
Operating Leases, Future Minimum Payments, Due in Rolling Year Four 103,114
Operating Leases, Future Minimum Payments, Due in Rolling Year Five 95,650
Operating Leases, Future Minimum Payments, Due Thereafter 33,112
Operating Leases, Future Minimum Payments Due, Gross 809,679
Less: imputed interest 70,124
Operating Leases, Future Minimum Payments Due $ 739,555
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 9 - EQUITY (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Common Stock, Shares Authorized         100,000,000   100,000,000
Common Stock, Par or Stated Value Per Share         $ 0.0001   $ 0.0001
Common Stock, Shares, Outstanding         77,226,355   70,590,898
Stock Issued During Period, Value, Issued for Services   $ 3,060,250 $ 5,120,250 $ 5,000 $ 3,187,679    
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 70,000 $ 35,000 $ 1,019,800 $ 505,200 $ 130,000    
Stock Issued During Period, Value, Acquisitions           $ 500,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number         6,059,998    
Stock Issuance 1              
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants           1,534,999  
Stock Issuance 2              
Stock Issued During Period, Value, Issued for Services           $ 7,792,000  
Common Stock              
Stock Issued During Period, Shares, Issued for Services   6,108,000 10,240,500 10,000 6,375,357    
Stock Issued During Period, Value, Issued for Services   $ 611 $ 1,024 $ 1      
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants 140,000 70,000 1,868,500 898,000 260,000    
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants $ 14 $ 7 $ 187 $ 90      
Stock Issued During Period, Shares, Acquisitions           1,000,000  
Common Stock | Stock Issuance 1              
Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants           2,773,900  
Common Stock | Stock Issuance 2              
Stock Issued During Period, Shares, Issued for Services           15,584,000  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.1
NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details)
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Details  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number | shares 6,059,998
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 4 months 20 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares $ 1.25
EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 104 176 1 false 26 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical Sheet http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets - Parenthetical Statements 3 false false R4.htm 000040 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 000050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 000060 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000090 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipment NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT Notes 9 false false R10.htm 000100 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperations NOTE 4 - DISCONTINUED OPERATIONS Notes 10 false false R11.htm 000110 - Disclosure - NOTE 5 - MORTGAGES PAYABLE Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayable NOTE 5 - MORTGAGES PAYABLE Notes 11 false false R12.htm 000120 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactions NOTE 6 - RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 000130 - Disclosure - NOTE 7 - LINE OF CREDIT Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCredit NOTE 7 - LINE OF CREDIT Notes 13 false false R14.htm 000140 - Disclosure - NOTE 8 - LEASES Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8Leases NOTE 8 - LEASES Notes 14 false false R15.htm 000150 - Disclosure - NOTE 9 - EQUITY Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9Equity NOTE 9 - EQUITY Notes 15 false false R16.htm 000160 - Disclosure - NOTE 10 - COMMITMENTS AND CONTINGENCIES Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote10CommitmentsAndContingencies NOTE 10 - COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 000170 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote11SubsequentEvents NOTE 11 - SUBSEQUENT EVENTS Notes 17 false false R18.htm 000180 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies) Policies 18 false false R19.htm 000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies) Policies 19 false false R20.htm 000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesManagementSRepresentationOfInterimCondensedFinancialStatementsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies) Policies 20 false false R21.htm 000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies) Policies 21 false false R22.htm 000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesSegmentReportingPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies) Policies 22 false false R23.htm 000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies) Policies 23 false false R24.htm 000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies) Policies 24 false false R25.htm 000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies) Policies 25 false false R26.htm 000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies) Policies 26 false false R27.htm 000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies) Policies 27 false false R28.htm 000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies) Policies 28 false false R29.htm 000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockPurchaseWarrantsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies) Policies 29 false false R30.htm 000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies) Policies 30 false false R31.htm 000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesNetLossPerSharePolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies) Policies 31 false false R32.htm 000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies) Policies 32 false false R33.htm 000330 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables) Tables 33 false false R34.htm 000340 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsTables NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables) Tables 34 false false R35.htm 000350 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtTables NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables) Tables 35 false false R36.htm 000360 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesTables NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables) Tables 36 false false R37.htm 000370 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesTables NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables) Tables 37 false false R38.htm 000380 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityTables NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables) Tables 38 false false R39.htm 000390 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusinessDetails NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness 39 false false R40.htm 000400 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies 40 false false R41.htm 000410 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsPolicies 41 false false R42.htm 000420 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies 42 false false R43.htm 000430 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies 43 false false R44.htm 000440 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesDetails NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies 44 false false R45.htm 000450 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables 45 false false R46.htm 000460 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsTables 46 false false R47.htm 000470 - Disclosure - NOTE 5 - MORTGAGES PAYABLE (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails NOTE 5 - MORTGAGES PAYABLE (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtTables 47 false false R48.htm 000480 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtTables 48 false false R49.htm 000490 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails NOTE 6 - RELATED PARTY TRANSACTIONS (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactions 49 false false R50.htm 000500 - Disclosure - NOTE 7 - LINE OF CREDIT (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCreditDetails NOTE 7 - LINE OF CREDIT (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCredit 50 false false R51.htm 000510 - Disclosure - NOTE 8 - LEASES (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails NOTE 8 - LEASES (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesTables 51 false false R52.htm 000520 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesTables 52 false false R53.htm 000530 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesTables 53 false false R54.htm 000540 - Disclosure - NOTE 9 - EQUITY (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails NOTE 9 - EQUITY (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityTables 54 false false R55.htm 000550 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details) Sheet http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityDetails NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details) Details http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityTables 55 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept RelatedAndNonrelatedPartyStatusAxis in us-gaap/2023 used in 14 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. yohe-20230930.htm 2816, 2818, 2820 [DQC.US.0043.9873] The company has reported the concept IncomeLossFromDiscontinuedOperationsNetOfTax as part of the cash flow statement. This income item is being added to the value of operating cash flows in the calculation defined by the filer. This implies that the resulting operating cash flow calculation includes this income item in cash flow from operations. If IncomeLossFromDiscontinuedOperationsNetOfTax represents income from discontinued operations then the element NetCashProvidedByUsedInOperatingActivities should be used as the total rather than the current total element of NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 3606, 4594 - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 3606, 4594 [dqc-0084-Durational-Aggregation] Sum of the cumulative periods of -9806765.000000 for NetIncomeLoss does not match the reported total of -9806766.000000, a difference of 1.000000. Period values are: 2022-01-01/2022-03-31 -520868, 2022-04-01/2022-06-30 -5631505, 2022-07-01/2022-09-30 -3654392. This rule takes into account possible rounding of values across periods and the decimals associated with each fact. This rule used a tolerance of 3 which is calculated by taking the lowest decimal value used in the calculation of inf. If there is a difference between the sum of the periods and the aggregate value reported the difference may be due to incorrect decimals associated with the individual fact values. The filer should check that the fact values do not have a decimal value that implies a higher level of accuracy than intended. In those rare cases where there are small immaterial differences that are less than 1% of the total and decimals are zero the rule can be overidden. This is performed by creating an extension element called ImmaterialDifferenceFlag. If this element has any value in any context in the instance then the immaterial difference will not result in an error. The rule excludes elements in the base taxonomy that cannot be aggregated such as an average, maximum or minimum value. The properties of this NetIncomeLoss fact are: Context: D220101_220930, Unit: USD. yohe-20230930.htm 1608, 1786, 1874, 2287 yohe-20230930.htm yohe-20230930.xsd yohe-20230930_cal.xml yohe-20230930_def.xml yohe-20230930_lab.xml yohe-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "yohe-20230930.htm": { "nsprefix": "fil", "nsuri": "http://www.yohealthinc.com/20230930", "dts": { "inline": { "local": [ "yohe-20230930.htm" ] }, "schema": { "local": [ "yohe-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "yohe-20230930_cal.xml" ] }, "definitionLink": { "local": [ "yohe-20230930_def.xml" ] }, "labelLink": { "local": [ "yohe-20230930_lab.xml" ] }, "presentationLink": { "local": [ "yohe-20230930_pre.xml" ] } }, "keyStandard": 162, "keyCustom": 14, "axisStandard": 6, "axisCustom": 1, "memberStandard": 9, "memberCustom": 17, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 104, "entityCount": 1, "segmentCount": 26, "elementCount": 236, "unitCount": 3, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 397, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation", "longName": "000010 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "D230101_230930", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets", "longName": "000020 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23Q3", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R3": { "role": "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "000030 - Statement - Condensed Consolidated Balance Sheets - Parenthetical", "shortName": "Condensed Consolidated Balance Sheets - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "UsdPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "E23Q3", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R4": { "role": "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations", "longName": "000040 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Y23Q3", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23Q3", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "000050 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "E21_StEqComps-CommonStock", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "Y22Q1_StEqComps-AddPaidInCap", "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R6": { "role": "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "000060 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "fil:StockBasedCompensationNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R7": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness", "longName": "000070 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "shortName": "NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies", "longName": "000080 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipment", "longName": "000090 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT", "shortName": "NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperations", "longName": "000100 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS", "shortName": "NOTE 4 - DISCONTINUED OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayable", "longName": "000110 - Disclosure - NOTE 5 - MORTGAGES PAYABLE", "shortName": "NOTE 5 - MORTGAGES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactions", "longName": "000120 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS", "shortName": "NOTE 6 - RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCredit", "longName": "000130 - Disclosure - NOTE 7 - LINE OF CREDIT", "shortName": "NOTE 7 - LINE OF CREDIT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8Leases", "longName": "000140 - Disclosure - NOTE 8 - LEASES", "shortName": "NOTE 8 - LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9Equity", "longName": "000150 - Disclosure - NOTE 9 - EQUITY", "shortName": "NOTE 9 - EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote10CommitmentsAndContingencies", "longName": "000160 - Disclosure - NOTE 10 - COMMITMENTS AND CONTINGENCIES", "shortName": "NOTE 10 - COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote11SubsequentEvents", "longName": "000170 - Disclosure - NOTE 11 - SUBSEQUENT EVENTS", "shortName": "NOTE 11 - SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies", "longName": "000180 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernPolicies", "longName": "000190 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesManagementSRepresentationOfInterimCondensedFinancialStatementsPolicies", "longName": "000200 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Management's Representation of Interim Condensed Financial Statements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "D230101_230930", "name": "fil:ManagementSRepresentationOfInterimFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "fil:ManagementSRepresentationOfInterimFinancialStatementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies", "longName": "000210 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesSegmentReportingPolicies", "longName": "000220 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segment Reporting (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsPolicies", "longName": "000230 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies", "longName": "000240 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies", "longName": "000250 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies", "longName": "000260 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies", "longName": "000270 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock-based Compensation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesPolicies", "longName": "000280 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockPurchaseWarrantsPolicies", "longName": "000290 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock Purchase Warrants (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "D230101_230930", "name": "fil:CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "fil:CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies", "longName": "000300 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: INCOME TAXES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "30", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:IncomeTaxPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:IncomeTaxPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesNetLossPerSharePolicies", "longName": "000310 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Net Loss Per Share (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies", "longName": "000320 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent Accounting Pronouncements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables", "longName": "000330 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables)", "shortName": "NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsTables", "longName": "000340 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables)", "shortName": "NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtTables", "longName": "000350 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables)", "shortName": "NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesTables", "longName": "000360 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables)", "shortName": "NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesTables", "longName": "000370 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables)", "shortName": "NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityTables", "longName": "000380 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables)", "shortName": "NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusinessDetails", "longName": "000390 - Disclosure - NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)", "shortName": "NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "D230101_230930", "name": "fil:EntityIncorporationStateCountryName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "fil:EntityIncorporationStateCountryName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernDetails", "longName": "000400 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Y23Q3", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails", "longName": "000410 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Goodwill and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Y22", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y22", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "longName": "000420 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "E22Q3", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R43": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "longName": "000430 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesDetails", "longName": "000440 - Disclosure - NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details)", "shortName": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "E23Q3", "name": "fil:RightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23Q3", "name": "fil:RightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails", "longName": "000450 - Disclosure - NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details)", "shortName": "NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT: Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "E23Q3_PpeByType-ComputerEquipment", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23Q3_PpeByType-ComputerEquipment", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails", "longName": "000460 - Disclosure - NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details)", "shortName": "NOTE 4 - DISCONTINUED OPERATIONS: Disposal Groups, Including Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Y23Q3", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "kbd", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y23Q3", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "kbd", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "longName": "000470 - Disclosure - NOTE 5 - MORTGAGES PAYABLE (Details)", "shortName": "NOTE 5 - MORTGAGES PAYABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:SecuredDebtOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "D230101_230930_CreditFacility-CnbBankOhStore", "name": "us-gaap:InterestExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R48": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails", "longName": "000480 - Disclosure - NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details)", "shortName": "NOTE 5 - MORTGAGES PAYABLE: Schedule of Maturities of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23Q3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "128", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "longName": "000490 - Disclosure - NOTE 6 - RELATED PARTY TRANSACTIONS (Details)", "shortName": "NOTE 6 - RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Y22Q3", "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "kbd", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "D230101_230930_RelatedAndNonrelatedPartyStatus-PeterAndVilaThawnghmung", "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R50": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCreditDetails", "longName": "000500 - Disclosure - NOTE 7 - LINE OF CREDIT (Details)", "shortName": "NOTE 7 - LINE OF CREDIT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DebtInstrumentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:DebtInstrumentDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails", "longName": "000510 - Disclosure - NOTE 8 - LEASES (Details)", "shortName": "NOTE 8 - LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Y22", "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Y22", "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails", "longName": "000520 - Disclosure - NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details)", "shortName": "NOTE 8 - LEASES: Schedule of lease costs and other information relating to the Company's operating leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "longName": "000530 - Disclosure - NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details)", "shortName": "NOTE 8 - LEASES: Schedule of Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "E23Q3", "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "longName": "000540 - Disclosure - NOTE 9 - EQUITY (Details)", "shortName": "NOTE 9 - EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "D220101_220930", "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } }, "R55": { "role": "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityDetails", "longName": "000550 - Disclosure - NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details)", "shortName": "NOTE 9 - EQUITY: Share-Based Payment Arrangement, Option, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "E23Q3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "D230101_230930", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "yohe-20230930.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r420" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r121", "r177", "r178", "r410" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation", "negatedLabel": "Accumulated Depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r30", "r119", "r309" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r61", "r420", "r470" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r238", "r239", "r240", "r328", "r446", "r447", "r448", "r456", "r474" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "fil_AriannaPhrakornkhamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "AriannaPhrakornkhamMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Arianna Phrakornkham", "documentation": "Represents the Arianna Phrakornkham, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total Assets", "totalLabel": "Total Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r89", "r120", "r137", "r155", "r168", "r172", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r256", "r258", "r269", "r303", "r353", "r420", "r432", "r452", "r453", "r460" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total current assets", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r116", "r123", "r137", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r256", "r258", "r269", "r420", "r452", "r453", "r460" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "fil_BasicAndDilutedEarningsLossPerCommonShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "BasicAndDilutedEarningsLossPerCommonShare", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from continuing operations {1}", "terseLabel": "Loss from continuing operations", "documentation": "Represents the per-share monetary value of Basic and diluted earnings (loss) per common share, during the indicated time period." } } }, "auth_ref": [] }, "fil_BasicAndDilutedEarningsLossPerCommonShareFromDiscontinuedOperations": { "xbrltype": "perShareItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "BasicAndDilutedEarningsLossPerCommonShareFromDiscontinuedOperations", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (loss) from discontinued operations {1}", "terseLabel": "Income (loss) from discontinued operations", "documentation": "Represents the per-share monetary value of Basic And Diluted Earnings Loss Per Common Share From Discontinued Operations, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccounting", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r78" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Building", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r82" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r102", "r304", "r329", "r348", "r420", "r432", "r439" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r21" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash At The Beginning Of The Period", "periodStartLabel": "Cash At The Beginning Of The Period", "periodEndLabel": "Cash At The End Of The Period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r75", "r133" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Increase (Decrease) In Cash", "totalLabel": "Net Increase (Decrease) In Cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r75" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "fil_CnbBankOhStoreMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "CnbBankOhStoreMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "CNB Bank- OH Store", "documentation": "Represents the CNB Bank- OH Store, during the indicated time period." } } }, "auth_ref": [] }, "fil_ColumbusOhio2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "ColumbusOhio2Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Columbus, Ohio - 2", "documentation": "Represents the Columbus, Ohio - 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_ColumbusOhioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "ColumbusOhioMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Columbus, Ohio", "documentation": "Represents the Columbus, Ohio, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote10CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "NOTE 10 - COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r84", "r186", "r187", "r397", "r451" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r422", "r423", "r424", "r426", "r427", "r428", "r429", "r446", "r447", "r456", "r469", "r474" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r60" ] }, "fil_CommonStockPurchaseWarrantsPolicyTextblockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "CommonStockPurchaseWarrantsPolicyTextblockTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockPurchaseWarrantsPolicies" ], "lang": { "en-us": { "role": { "label": "Stock Purchase Warrants", "documentation": "Represents the textual narrative disclosure of Stock Purchase Warrants, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r60", "r340" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r60", "r340", "r359", "r474", "r475" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value; 100,000,000 shares authorized, 77,226,355 and 70,590,898 outstanding as of September 30, 2023 and December 31 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r60", "r305", "r420" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r70", "r137", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r269", "r452" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Fiscal Year End", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayable" ], "lang": { "en-us": { "role": { "label": "NOTE 5 - MORTGAGES PAYABLE", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r85", "r135", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCreditDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r13", "r31", "r39", "r58", "r90", "r91" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r29" ] }, "us-gaap_DepreciationExpenseOnReclassifiedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationExpenseOnReclassifiedAssets", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation Expense on Reclassified Assets", "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Notes" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r52", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Gross Profit {1}", "terseLabel": "Gross Profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r52", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r52" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue {1}", "terseLabel": "Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r52", "r115" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "NOTE 4 - DISCONTINUED OPERATIONS", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r40", "r81" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r434" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r435" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesNetLossPerSharePolicies" ], "lang": { "en-us": { "role": { "label": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r22", "r23" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Registrant CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r433" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r433" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r437" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r433" ] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "fil_EntityIncorporationStateCountryName": { "xbrltype": "stringItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "EntityIncorporationStateCountryName", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Name", "documentation": "Represents the description of Entity Incorporation State Country Name, during the indicated time period." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r436" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r433" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r433" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r433" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r433" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r113", "r127", "r128", "r129", "r140", "r141", "r142", "r144", "r149", "r151", "r154", "r180", "r181", "r224", "r238", "r239", "r240", "r252", "r253", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r270", "r271", "r272", "r273", "r274", "r275", "r287", "r316", "r317", "r318", "r328", "r382" ] }, "fil_FlushingNewYorkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "FlushingNewYorkMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Flushing, New York", "documentation": "Represents the Flushing, New York, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other assets {1}", "negatedLabel": "Other assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r442" ] }, "fil_GainOnTheSaleOfBuilding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "GainOnTheSaleOfBuilding", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain on the sale of building", "documentation": "Represents the monetary amount of Gain on the sale of building, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnSalesOfOtherRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfOtherRealEstate", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain on the sale of building {1}", "negatedLabel": "Gain on the sale of building", "documentation": "The net gain (loss) resulting from sales and other disposals of other real estate owned, increases (decreases) in the valuation allowance for foreclosed real estate, and write-downs of other real estate owned after acquisition or physical possession." } } }, "auth_ref": [ "r95" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r71", "r363" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r182", "r185", "r416" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r5", "r183", "r184", "r185", "r416" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross profit (loss)", "totalLabel": "Gross profit (loss)", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r68", "r137", "r155", "r167", "r171", "r173", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r269", "r413", "r452" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from continuing operations", "totalLabel": "Loss from continuing operations", "negatedLabel": "Loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r36", "r69", "r77", "r145", "r146", "r147", "r148", "r152", "r153" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss before provision for income taxes", "totalLabel": "Loss before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r66", "r93", "r155", "r167", "r171", "r173", "r301", "r311", "r413" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (loss) from discontinued operations", "verboseLabel": "Less: income (loss) from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r42", "r43", "r44", "r45", "r46", "r54", "r115", "r255", "r312" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Provision (credit) for income tax", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r101", "r111", "r150", "r151", "r159", "r247", "r254", "r314" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r126", "r245", "r246", "r248", "r249", "r250", "r251", "r322" ] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts receivable {1}", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts receivable other", "negatedLabel": "Accounts receivable other", "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other." } } }, "auth_ref": [ "r441" ] }, "us-gaap_IncreaseDecreaseInNotesPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInNotesPayableRelatedParties", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Notes payable related parties {1}", "terseLabel": "Notes payable related parties", "documentation": "The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r438", "r441" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayable", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Mortgage payable", "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSecurityDeposits", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Security deposits {1}", "terseLabel": "Security deposits", "documentation": "The increase (decrease) during the reporting period in security deposits." } } }, "auth_ref": [ "r4" ] }, "fil_IncreaseDecreaseInSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "IncreaseDecreaseInSubscriptionsReceivable", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Subscriptions receivable", "documentation": "Represents the monetary amount of Increase decrease in subscriptions receivable, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedTrademarks": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedTrademarks", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Trademarks", "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit." } } }, "auth_ref": [ "r80" ] }, "fil_IndianapolisIndiana1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "IndianapolisIndiana1Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Indianapolis, Indiana - 1", "documentation": "Represents the Indianapolis, Indiana - 1, during the indicated time period." } } }, "auth_ref": [] }, "fil_IndianapolisIndiana2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "IndianapolisIndiana2Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Indianapolis, Indiana - 2", "documentation": "Represents the Indianapolis, Indiana - 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_IndianapolisIndiana3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "IndianapolisIndiana3Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Indianapolis, Indiana - 3", "documentation": "Represents the Indianapolis, Indiana - 3, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsCurrent", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions." } } }, "auth_ref": [ "r2" ] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndOtherIncome", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r38", "r96", "r130", "r158", "r276", "r367", "r430", "r471" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land {1}", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r455" ] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseAndRentalExpense", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Rent expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r282", "r419" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease costs and other information relating to the Company's operating leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r459" ] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8Leases" ], "lang": { "en-us": { "role": { "label": "NOTE 8 - LEASES", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r277" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r281" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total Liabilities", "totalLabel": "Total Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r137", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r257", "r258", "r259", "r269", "r339", "r412", "r432", "r452", "r460", "r461" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total liabilities and shareholders' deficit", "totalLabel": "Total liabilities and shareholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r65", "r92", "r307", "r420", "r444", "r449", "r457" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total current liabilities", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r117", "r137", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r257", "r258", "r259", "r269", "r420", "r452", "r460", "r461" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r13", "r91", "r468" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturities, Repayments of Principal in Next Rolling 12 Months", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r445" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r445" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r445" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r445" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturities, Repayments of Principal in Rolling Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r445" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote7LineOfCredit" ], "lang": { "en-us": { "role": { "label": "NOTE 7 - LINE OF CREDIT", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r85" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "fil_ManagementSRepresentationOfInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "ManagementSRepresentationOfInterimFinancialStatementsPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesManagementSRepresentationOfInterimCondensedFinancialStatementsPolicies" ], "lang": { "en-us": { "role": { "label": "Management's Representation of Interim Condensed Financial Statements", "documentation": "Represents the textual narrative disclosure of Management's Representation of Interim Financial Statements Policy, during the indicated time period." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r226", "r299", "r315", "r331", "r332", "r389", "r390", "r391", "r392", "r393", "r407", "r408", "r415", "r417", "r418", "r421", "r454", "r462", "r463", "r464", "r465", "r466", "r467" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r226", "r299", "r315", "r331", "r332", "r389", "r390", "r391", "r392", "r393", "r407", "r408", "r415", "r417", "r418", "r421", "r454", "r462", "r463", "r464", "r465", "r466", "r467" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Real Estate" } } }, "auth_ref": [ "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ] }, "fil_N7kFarmsReOldNationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "N7kFarmsReOldNationalMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "7K Farms RE - Old National", "documentation": "Represents the 7K Farms RE - Old National, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote1OrganizationAndDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r103", "r112" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash provided by investing activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r132" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows (used in) investing activities", "totalLabel": "Cash flows (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r132" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash (used in) operating activities", "totalLabel": "Net cash (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities {1}", "terseLabel": "Net Cash Provided by (Used in) Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash used in operating activities -continuing operations", "totalLabel": "Net cash used in operating activities -continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "fil_NetCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "NetCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net cash provided by (used in) operating activities -discontinued operations", "documentation": "Represents the monetary amount of Net cash provided by (used in) operating activities -discontinued operations, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 }, "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r67", "r77", "r94", "r115", "r124", "r125", "r129", "r137", "r143", "r145", "r146", "r147", "r148", "r150", "r151", "r152", "r155", "r167", "r171", "r173", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r268", "r269", "r313", "r361", "r380", "r381", "r413", "r430", "r452" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "fil_NotesPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "NotesPayableRelatedParties", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes payable related parties", "documentation": "Represents the monetary amount of Notes payable related parties, as of the indicated date." } } }, "auth_ref": [] }, "fil_OldNational7kFarmsFactoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "OldNational7kFarmsFactoryMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Old National - 7K farms - Factory", "documentation": "Represents the Old National - 7K farms - Factory, during the indicated time period." } } }, "auth_ref": [] }, "fil_OldNationalBankLaStoreFacMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "OldNationalBankLaStoreFacMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Old National Bank- LA Store/Fac", "documentation": "Represents the Old National Bank- LA Store/Fac, during the indicated time period." } } }, "auth_ref": [] }, "fil_OldNationalLoanInFactoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "OldNationalLoanInFactoryMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Old National Loan- IN Factory", "documentation": "Represents the Old National Loan- IN Factory, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total operating expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss from operations", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r155", "r167", "r171", "r173", "r413" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r283", "r419" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Less: imputed interest", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r458" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r279" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Lease liabilities short term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r279" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long term lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r279" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r280", "r286" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r278" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDue", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due", "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year." } } }, "auth_ref": [ "r98", "r100" ] }, "fil_OperatingLeasesFutureMinimumPaymentsDueGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "OperatingLeasesFutureMinimumPaymentsDueGross", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Gross", "documentation": "Represents the monetary amount of Operating Leases, Future Minimum Payments Due, Gross, as of the indicated date." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Rolling Year Five", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Rolling Year Four", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Rolling Year Three", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due in Rolling Year Two", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [ "r98", "r100" ] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments, Next Rolling 12 Months", "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r122", "r420" ] }, "us-gaap_OtherExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherExpensesAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses {1}", "terseLabel": "Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expense, net", "totalLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r72" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income(expense)" } } }, "auth_ref": [] }, "fil_OtherRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "OtherRelatedPartiesMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Other Related Parties", "documentation": "Represents the Other Related Parties, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Property and equipment -asset purchase", "negatedLabel": "Property and equipment -asset purchase", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r74" ] }, "fil_PeterAndVilaThawnghmungMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "PeterAndVilaThawnghmungMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Peter and Vila Thawnghmung", "documentation": "Represents the Peter and Vila Thawnghmung, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "lang": { "en-us": { "role": { "label": "Policies" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r19", "r443" ] }, "us-gaap_ProceedsFromSaleOfBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfBuildings", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of property", "documentation": "The cash inflow from sale of buildings." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r430", "r472", "r473" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "NOTE 3 - PROPERTY, PLANT, AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r81", "r106", "r109", "r110" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross Carrying Amount", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r82", "r118", "r310" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r302", "r310", "r420" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r106", "r109", "r308" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r82" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r225", "r226", "r234", "r235", "r236", "r298", "r299", "r315", "r331", "r332", "r389", "r390", "r391", "r392", "r393", "r407", "r408", "r415", "r417", "r418", "r421", "r424", "r450", "r454", "r463", "r464", "r465", "r466", "r467" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement" } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r225", "r226", "r234", "r235", "r236", "r298", "r299", "r315", "r331", "r332", "r389", "r390", "r391", "r392", "r393", "r407", "r408", "r415", "r417", "r418", "r421", "r424", "r450", "r454", "r463", "r464", "r465", "r466", "r467" ] }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Party Status [Axis]", "documentation": "Information by related and nonrelated party status." } } }, "auth_ref": [ "r138", "r139", "r291", "r292", "r293", "r294", "r334", "r335", "r336", "r337", "r338", "r358", "r360", "r425" ] }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Party Status", "documentation": "Related and nonrelated party status." } } }, "auth_ref": [ "r138", "r139", "r291", "r292", "r293", "r294", "r334", "r335", "r336", "r337", "r338", "r358", "r360", "r425" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "NOTE 6 - RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r288", "r289", "r290", "r292", "r295", "r324", "r325", "r326", "r364", "r365", "r366", "r386", "r388" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r62", "r87", "r306", "r319", "r320", "r323", "r341", "r420" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r113", "r140", "r141", "r142", "r144", "r149", "r151", "r180", "r181", "r238", "r239", "r240", "r252", "r253", "r260", "r262", "r263", "r265", "r267", "r316", "r318", "r328", "r474" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r362", "r409", "r411" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r131", "r137", "r156", "r157", "r166", "r169", "r170", "r174", "r175", "r176", "r179", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r269", "r301", "r452" ] }, "fil_RightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "RightOfUseAsset", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Right of Use Asset", "documentation": "Represents the monetary amount of Right of Use Asset, as of the indicated date." } } }, "auth_ref": [] }, "fil_RomeThalopMember": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "RomeThalopMember", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Rome Thalop", "documentation": "Represents the Rome Thalop, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote4DiscontinuedOperationsDisposalGroupsIncludingDiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r8", "r12", "r14", "r41", "r47", "r48", "r49", "r50", "r51", "r53", "r55", "r56", "r83" ] }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfMaturitiesOfLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Lease Liabilities", "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r32" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtCurrent", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r58", "r90" ] }, "us-gaap_SecuredDebtOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtOther", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Mortgage liabilities", "documentation": "Amount of collateralized debt obligations classified as other." } } }, "auth_ref": [ "r97" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Security deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r440" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesSegmentReportingPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r160", "r161", "r162", "r163", "r164", "r165", "r175", "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r229", "r230" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r229", "r230" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r227", "r228", "r231", "r232", "r233", "r234", "r237", "r241", "r242", "r243", "r244" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityShareBasedPaymentArrangementOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r88" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding, Beginning Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance", "periodEndLabel": "Shares, Outstanding, Ending Balance", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r284", "r419" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r78", "r134" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r18", "r113", "r127", "r128", "r129", "r140", "r141", "r142", "r144", "r149", "r151", "r154", "r180", "r181", "r224", "r238", "r239", "r240", "r252", "r253", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r270", "r271", "r272", "r273", "r274", "r275", "r287", "r316", "r317", "r318", "r328", "r382" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r140", "r141", "r142", "r154", "r300", "r321", "r330", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r360", "r362", "r363", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r425" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets", "verboseLabel": "Condensed Consolidated Balance Sheets - Parenthetical" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote3PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote5MortgagesPayableDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r140", "r141", "r142", "r154", "r300", "r321", "r330", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r360", "r362", "r363", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r382", "r425" ] }, "fil_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants", "documentation": "Represents the Stock And Warrants Issued During Period, Shares, Preferred Stock And Warrants (number of shares), during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "fil_StockBasedCompensationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockBasedCompensationNet", "crdr": "debit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Represents the monetary amount of Stock based compensation, Net, during the indicated time period." } } }, "auth_ref": [] }, "fil_StockIssuance1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockIssuance1Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issuance 1", "documentation": "Represents the Stock Issuance 1, during the indicated time period." } } }, "auth_ref": [] }, "fil_StockIssuance2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockIssuance2Member", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issuance 2", "documentation": "Represents the Stock Issuance 2, during the indicated time period." } } }, "auth_ref": [] }, "fil_StockIssuanceAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockIssuanceAxis", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issuance [Axis]", "documentation": "Represents the description of Stock Issuance, during the indicated time period." } } }, "auth_ref": [] }, "fil_StockIssuanceDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "StockIssuanceDomain", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issuance", "documentation": "Represents the Stock Issuance, during the indicated time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r59", "r60", "r87" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r9", "r59", "r60", "r87" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r9", "r18", "r87" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote6RelatedPartyTransactionsDetails", "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9EquityDetails", "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r33", "r59", "r60", "r87" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Total shareholders' deficit", "totalLabel": "Total shareholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r60", "r63", "r64", "r79", "r342", "r359", "r383", "r384", "r420", "r432", "r444", "r449", "r457", "r474" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Shareholders' deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance", "periodStartLabel": "Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance", "periodEndLabel": "Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r34", "r35", "r37", "r113", "r114", "r128", "r140", "r141", "r142", "r144", "r149", "r180", "r181", "r224", "r238", "r239", "r240", "r252", "r253", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r270", "r271", "r275", "r287", "r317", "r318", "r327", "r342", "r359", "r383", "r384", "r394", "r431", "r444", "r449", "r457", "r474" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote9Equity" ], "lang": { "en-us": { "role": { "label": "NOTE 9 - EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r86", "r136", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r266", "r385", "r387", "r395" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote11SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "NOTE 11 - SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r296", "r297" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesGoingConcernPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r57" ] }, "us-gaap_TableTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Tables/Schedules" } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Details" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote2SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r24", "r25", "r26", "r104", "r105", "r107", "r108" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_DisclosureNote8LeasesScheduleOfLeaseCostsAndOtherInformationRelatingToTheCompanySOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r285", "r419" ] }, "fil_WeightedAverageNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.yohealthinc.com/20230930", "localname": "WeightedAverageNumberOfSharesOutstanding", "presentation": [ "http://www.yohealthinc.com/20230930/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding", "documentation": "Represents the Weighted average number of shares outstanding (number of shares), during the indicated time period." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "35", "Paragraph": "44", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-44" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-7" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480876/942-470-45-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Subparagraph": "(Note 3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 74 0001096906-24-000484-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-24-000484-xbrl.zip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yohe-20230930_htm.xml IDEA: XBRL DOCUMENT 0001844793 2023-01-01 2023-09-30 0001844793 2023-09-30 0001844793 2024-03-18 0001844793 2022-12-31 0001844793 2023-07-01 2023-09-30 0001844793 2022-07-01 2022-09-30 0001844793 2022-01-01 2022-09-30 0001844793 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 2021-12-31 0001844793 us-gaap:CommonStockMember 2021-12-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001844793 us-gaap:RetainedEarningsMember 2021-12-31 0001844793 2022-01-01 2022-03-31 0001844793 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001844793 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001844793 2022-03-31 0001844793 us-gaap:CommonStockMember 2022-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001844793 us-gaap:RetainedEarningsMember 2022-03-31 0001844793 2022-04-01 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001844793 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001844793 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001844793 us-gaap:RetainedEarningsMember 2022-06-30 0001844793 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001844793 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001844793 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001844793 us-gaap:RetainedEarningsMember 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-12-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001844793 us-gaap:RetainedEarningsMember 2022-12-31 0001844793 2023-01-01 2023-03-31 0001844793 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001844793 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001844793 2023-03-31 0001844793 us-gaap:CommonStockMember 2023-03-31 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001844793 us-gaap:RetainedEarningsMember 2023-03-31 0001844793 2023-04-01 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001844793 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001844793 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-06-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001844793 us-gaap:RetainedEarningsMember 2023-06-30 0001844793 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001844793 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001844793 us-gaap:CommonStockMember 2023-09-30 0001844793 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001844793 us-gaap:RetainedEarningsMember 2023-09-30 0001844793 2022-01-01 2022-12-31 0001844793 2021-01-01 2021-12-31 0001844793 us-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-09-30 0001844793 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-09-30 0001844793 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-09-30 0001844793 us-gaap:BuildingMember 2023-09-30 0001844793 us-gaap:ComputerEquipmentMember 2022-12-31 0001844793 us-gaap:LandMember 2023-09-30 0001844793 us-gaap:LandMember 2022-12-31 0001844793 fil:CnbBankOhStoreMember 2023-09-30 0001844793 fil:OldNationalBankLaStoreFacMember 2023-09-30 0001844793 fil:OldNationalLoanInFactoryMember 2023-09-30 0001844793 fil:OldNational7kFarmsFactoryMember 2023-09-30 0001844793 fil:CnbBankOhStoreMember 2023-01-01 2023-09-30 0001844793 fil:OldNationalLoanInFactoryMember 2023-01-01 2023-09-30 0001844793 fil:OldNationalBankLaStoreFacMember 2023-01-01 2023-09-30 0001844793 fil:N7kFarmsReOldNationalMember 2023-01-01 2023-09-30 0001844793 fil:PeterAndVilaThawnghmungMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001844793 fil:PeterAndVilaThawnghmungMember 2021-01-01 2021-12-31 0001844793 fil:OtherRelatedPartiesMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001844793 fil:OtherRelatedPartiesMember 2021-01-01 2021-12-31 0001844793 fil:PeterAndVilaThawnghmungMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:PeterAndVilaThawnghmungMember 2022-01-01 2022-09-30 0001844793 fil:AriannaPhrakornkhamMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:AriannaPhrakornkhamMember 2022-01-01 2022-09-30 0001844793 fil:OtherRelatedPartiesMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001844793 fil:OtherRelatedPartiesMember 2022-01-01 2022-09-30 0001844793 fil:PeterAndVilaThawnghmungMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 fil:PeterAndVilaThawnghmungMember 2023-01-01 2023-09-30 0001844793 fil:RomeThalopMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001844793 fil:RomeThalopMember 2023-01-01 2023-09-30 0001844793 fil:FlushingNewYorkMember 2023-01-01 2023-09-30 0001844793 fil:ColumbusOhioMember 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana1Member 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana2Member 2023-01-01 2023-09-30 0001844793 fil:IndianapolisIndiana3Member 2023-01-01 2023-09-30 0001844793 fil:ColumbusOhio2Member 2023-01-01 2023-09-30 0001844793 us-gaap:CommonStockMember fil:StockIssuance1Member 2022-01-01 2022-09-30 0001844793 fil:StockIssuance1Member 2022-01-01 2022-09-30 0001844793 us-gaap:CommonStockMember fil:StockIssuance2Member 2022-01-01 2022-09-30 0001844793 fil:StockIssuance2Member 2022-01-01 2022-09-30 0001844793 us-gaap:CommonStockMember 2022-01-01 2022-09-30 iso4217:USD shares iso4217:USD shares 0001844793 --12-31 false 2023 Q3 10-Q true 2023-09-30 false 333-222631 YO-HEALTH, INC. NV 85-3135038 7551 Shelby Street 3rd FL Indianapolis IN 46227 614 327-7630 Yes Yes Non-accelerated Filer true true false false 77717721 195803 124062 0 179298 195803 303361 3442091 4017136 40799 37999 900422 776405 6630 1200 29150 29150 4614894 5165250 225944 59233 204116 188113 484490 61490 255700 0 1170249 308836 737789 610930 1549713 1728883 3457751 2648649 0.0001 0.0001 100000000 100000000 77226355 77226355 70590898 70590898 7723 7059 20301605 16984590 -19152185 -14475048 1157143 2516601 4614894 5165250 2500311 201359 5718680 388253 1589775 326564 4303560 1189047 910536 -125204 1415120 -800793 1725370 3411220 5442108 8856872 54723 54605 254278 159341 57007 62938 193259 166490 1837100 3528763 5889645 9182703 -926564 -3653967 -4474525 -9983497 25718 11290 95869 34024 0 1817 0 1817 0 0 438 0 -25718 -9472 -95431 -32207 -952282 -3663439 -4569957 -10015704 0 0 0 0 -952282 -3663439 -4569957 -10015704 0 9047 -107180 208938 -952282 -3654392 -4677137 -9806766 -0.01 -0.05 -0.06 -0.16 0 0.00 -0.00 0.00 76661355 67338998 75054536 62272998 51232998 5123 7159526 -3593926 3570723 10000 1 4999 5000 898000 90 505110 505200 -520868 -520868 52140998 5214 7669635 -4114794 3560055 10240500 1024 5119226 5120250 1868500 187 1019613 1019800 -5631505 -5631505 64249998 6425 13808474 -9746299 4068600 6108000 611 3059639 3060250 70000 7 34993 35000 -3654392 -3654392 70427998 7043 16903106 -13400692 3509457 70590898 7059 16984590 -14475048 2516601 1110000 111 554889 555000 140000 14 69985 70000 -837652 -837652 71840898 7184 17609464 -15312700 2303949 4255457 426 2127254 2127680 -2887203 -2887203 76096355 7610 19736718 -18199903 1544424 1130000 113 564887 565000 -952282 -952282 77226355 7723 20301605 -19152185 1157143 -4569957 -10015704 -107180 208938 -4677137 -9806766 3247680 8185500 232222 34971 438 -179298 -110678 0 -7400 0 20000 5430 0 0 -6700 175305 50926 -34171 106611 -882670 -1297380 0 0 -882670 -1297380 49289 410312 -49289 -410312 423000 0 255700 0 255000 0 70000 1560000 1003700 1560000 71741 -147692 124062 1429587 195803 1281895 <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Nature of Operations</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">YO-Health, Inc. (“YO-Health” or the “Company”) was established as a C-Corporation in Nevada on October 22, 2020. The Company is the parent company to Yoshi Inc, Sun &amp; Moon Café, 7K Farms and Joyce’s Bakery Inc. YO-Health manufactures, retails, wholesales, and distributes premium, healthy, unique, and innovative food products.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company commenced operations in October 2020 by acquiring a Beijing-style premium yogurt store in Woodside, New York. The Company has since launched the subsidiaries Yoshi Restaurants, Inc., Sun &amp; Moon, and Joyce’s Bakery &amp; Café, Inc.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company currently has 4 Yoshi model restaurants, 1 Sun &amp; Moon Café and 1 yogurt manufacturing facility.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Each subsidiary company of YO-Health, Inc. will focus on their respective products on a wholesale and retail basis:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Sun &amp; Moon will produce, market, and sell yogurt-based items with probiotics and ingredients focused on beneficial healthy products.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Yoshi will produce, market, and sell Asian fusion food products.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Joyce’s Bakery &amp; Café will produce, market, and sell premium, Asian- French-inspired desserts, Tea’s, Juices, and flavored coffee with a full array of non-alcoholic drinks.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">7K Farms delivers wholesale food and supplies to the Company locations as well as other restaurant and grocery locations. </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation -see Note 4. Discontinued Operations.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">The Company’s accounting year-end is December 31.</p> Nevada 2020-10-22 <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Basis of Presentation</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The condensed consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Yoshi Inc, Sun &amp; Moon Café, and Joyce’s Bakery Inc.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Going Concern</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed consolidated financial statements.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For the nine months ended September 30, 2023, the Company had a loss from continuing operations of $4,569,957. As of September 30, 2023 the Company had an accumulated deficit of $19,152,185. The Company expects to generate operating cash flows that will be sufficient to fund presently anticipated operations although there can be no assurance. This raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing to supplement the expected cash flow.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its revenues support its operations.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company may attempt to raise capital in the near future through the sale of equity or debt financing; however, there can be assurances the Company will be successful in doing so. There can be no assurance that such additional financing will be available to the Company on acceptable terms or at all.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Management’s Representation of Interim Condensed Consolidated Financial Statements</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual condensed financial statements. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed financial statements include all of the adjustments, which in the opinion of management are necessary for a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Use of Estimates</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of goodwill, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable, and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Segment Reporting</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company operates in one segment, the food service business. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying condensed consolidated financial statements.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Goodwill and Intangible Assets</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill and indefinite-lived assets during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry, and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Indefinite-lived intangible assets are evaluated for impairment at the individual asset level by assessing whether it is more likely than not that the asset is impaired (for example, that the fair value of the asset is below its carrying amount). If it is more likely than not that the asset is impaired, its carrying amount is written down to its fair value.</p> <p style="font:12pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">We performed our annual fair value assessment on December 31, 2021, on our purchases of the New Orleans, Woodside, 7K Farms and the Champagne, Illinois acquisitions, and determined that an impairment charge of $750,000 and $1,000,000, respectively, was necessary for the years ended December 31, 2022, and 2021. As a result, we had no goodwill as of September 30, 2023, and December 31, 2022, respectively. The balance of indefinite-lived intangible assets comprised of trademarks were $40,799 and $37,399, respectively, as of September 30, 2023, and December 31, 2022.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Revenue Recognition</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company recognizes revenue under the guidelines of ASC 606. Sales, as presented in the Company’s statement of earnings, represent revenue; and food and beverage products sold which is presented net of discounts, coupons, employee meals and complimentary meals. Revenue is recognized using the five step approach required under the guidelines of ASC 606:</p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">1.</kbd>Identify the contract with the client, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">2.</kbd>Identify the performance obligations in the contract, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3.</kbd>Determine the transaction price, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">4.</kbd>Allocate the transaction price to performance obligations in the contract </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">5.</kbd>Recognize revenues when or as the Company satisfies a performance obligation </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For retail operations, all five steps of revenue recognition occur almost simultaneously. The customer orders food from a menu or store sign, it is given to the customer who then pays for the food order at the cash register. The Company’s store business represented approximately 27.6% and 100% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For wholesale sales the customer orders wholesale items from a store sign or catalogue, it is given or delivered to the customer who then pays for the items within 7 days of sale. The Company’s store business represented approximately 72.4% and 0% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Cash and Cash Equivalents</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On September 30, 2023, and December 31, 2022, the Company’s cash equivalents totaled $195,803 and $124,062 , respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Property and equipment</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Property and equipment are stated at cost or fair value. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expenses as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in the results of operations. The estimated useful lives of property and equipment are as follows:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="background-color:#CCEEFF;width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Computers, software, and office equipment</p> </td><td style="background-color:#CCEEFF;width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">1 – 6 years</p> </td></tr> <tr><td style="width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Machinery and equipment</p> </td><td style="width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">3 – 5 years</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Leasehold improvements</p> </td><td style="background-color:#CCEEFF;width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">Lesser of lease term or estimated useful life</p> </td></tr> <tr><td style="width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Buildings</p> </td><td style="width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">39 years</p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">Equipment that hasn’t been placed into service is not subject to depreciation.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Depreciation expense for the nine months ended September 30, 2023 and 2022 was $232,222 and $23,314, respectively.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Stock-based Compensation</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Leases</i></p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The Company currently follows the guidance in ASC 840 “<i>Leases</i>,” which requires us to evaluate the lease agreements the Company enters into to determine whether they represent operating or capital leases at the inception of the lease.</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), that requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The accounting treatment for finance leases and lessors remains relatively unchanged. The accounting standards update also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB approved an amendment to the new guidance that introduced an alternative modified retrospective transition approach granting companies the option of using the effective date of the new standard as the date of initial application. The Company adopted the standard using the effective date method on December 31, 2022.</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The Company elected the transition package of practical expedients that is permitted by the standard. The package of practical expedients allows the Company to not reassess previous accounting conclusions regarding whether existing arrangements are or contain leases, the classification of existing leases, and the treatment of initial direct costs. The Company did not elect the hindsight transition practical expedient allowed for by the new standard, which allows entities to use hindsight when determining lease term and impairment of ROU assets. Additionally, the Company elected certain other practical expedients offered by the new standard which it will apply to all asset classes, including the option not to separate lease and non-lease components and instead to account for them as a single lease component and the option not to recognize ROU assets and related liabilities that arise from short-term leases (i.e., leases with terms of twelve months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise).</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The standard had a material impact on the balance sheet on the date of adoption, with the most significant impact being the recognition of $900,422 operating lease right-of-use assets and $204,116 operating lease liabilities.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As part of its adoption of the new lease accounting standard, the Company also implemented new internal controls and updated accounting policies and procedures, operational processes and documentation practices to enable the preparation of financial information on adoption. Refer to Note 6: Leases - Accounting Principles and Leases for additional disclosures required as a result of the adoption of this new standard.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"><i>Stock Purchase Warrants</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify">The Company has issued warrants to purchase shares of its common stock. Warrants have been accounted for as equity in accordance with FASB ASC 480, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"><i>Income taxes</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company accounts for income taxes under FASB ASC 740, <i>“Accounting for Income Taxes”</i>. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">enactment date. FASB ASC 740-10-05, <i>“Accounting for Uncertainty in Income Taxes”</i> prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</p> <p style="font:10pt Times New Roman;margin:0;color:#333333;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="color:#333333;background-color:#FFFFFF">On Dec. 18, 2019, the Financial Accounting Standards Board (FASB) released Accounting Standards Update (ASU) 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The FASB has stated that the ASU is being issued as part of its Simplification Initiative, which is meant to reduce complexity in accounting standards by improving certain areas of generally accepted accounting principles (GAAP) without compromising information provided to users of condensed consolidated financial statements. </span><span style="background-color:#FFFFFF">The Company adopted this guidance on January 1, 2021, which had no impact on the Company’s condensed consolidated financial statements.</span></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"><i>Net Loss per Share</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, "Earnings per Share." Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and diluted common share equivalents outstanding.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:12pt Times New Roman;margin:0;text-align:justify"><span style="font-size:9pt;border-bottom:1px solid #000000"><i>Discontinued Operations</i></span></p> <p style="font:9pt Times New Roman;margin:0"> </p> <p style="font:12pt Times New Roman;margin:0;text-align:justify"><span style="font-size:9pt">The operations of the Company’s former Winn Sushi Division has been presented as discontinued operations. Unless otherwise noted, amounts and disclosures throughout these Notes to Condensed Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 4. for additional information on discontinued operations.</span></p> <p style="font:9pt Times New Roman;margin:0"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Recent Accounting Pronouncements</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i>, which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, <i>Codification Improvements</i>, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, <i>Codification Improvements to Topic 842, Leases </i>in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases <i>(Topic 842) Targeted Improvements,</i> which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard. On November 15, 2019, the FASB has issued ASU 2019-10, which amends the effective dates for three major accounting standards. The ASU defers the effective dates for the credit losses, derivatives, and lease standards for certain companies.   The Company adopted ASC 842 on December 31, 2022.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Basis of Presentation</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The condensed consolidated financial statements of the Company have been prepared in accordance with GAAP. This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses or recognized when incurred. The condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Yoshi Inc, Sun &amp; Moon Café, and Joyce’s Bakery Inc.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Going Concern</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these condensed consolidated financial statements.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For the nine months ended September 30, 2023, the Company had a loss from continuing operations of $4,569,957. As of September 30, 2023 the Company had an accumulated deficit of $19,152,185. The Company expects to generate operating cash flows that will be sufficient to fund presently anticipated operations although there can be no assurance. This raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing to supplement the expected cash flow.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its revenues support its operations.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company may attempt to raise capital in the near future through the sale of equity or debt financing; however, there can be assurances the Company will be successful in doing so. There can be no assurance that such additional financing will be available to the Company on acceptable terms or at all.</p> -4569957 -19152185 <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Management’s Representation of Interim Condensed Consolidated Financial Statements</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The accompanying unaudited condensed consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual condensed financial statements. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed financial statements include all of the adjustments, which in the opinion of management are necessary for a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Use of Estimates</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of goodwill, liabilities, and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable, and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Segment Reporting</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company operates in one segment, the food service business. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in economic characteristics; nature of products and services; and procurement, manufacturing, and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying condensed consolidated financial statements.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Goodwill and Intangible Assets</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from our acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. We perform an annual impairment assessment for goodwill and indefinite-lived assets during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, we determine fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, we rely on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, our risk relative to the overall market, our size and industry, and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures, and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Indefinite-lived intangible assets are evaluated for impairment at the individual asset level by assessing whether it is more likely than not that the asset is impaired (for example, that the fair value of the asset is below its carrying amount). If it is more likely than not that the asset is impaired, its carrying amount is written down to its fair value.</p> <p style="font:12pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Determining the fair value of a reporting unit is judgmental and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that our estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause us to perform an impairment test prior to scheduled annual impairment tests.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">We performed our annual fair value assessment on December 31, 2021, on our purchases of the New Orleans, Woodside, 7K Farms and the Champagne, Illinois acquisitions, and determined that an impairment charge of $750,000 and $1,000,000, respectively, was necessary for the years ended December 31, 2022, and 2021. As a result, we had no goodwill as of September 30, 2023, and December 31, 2022, respectively. The balance of indefinite-lived intangible assets comprised of trademarks were $40,799 and $37,399, respectively, as of September 30, 2023, and December 31, 2022.</p> 750000 1000000 40799 37399 <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Revenue Recognition</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company recognizes revenue under the guidelines of ASC 606. Sales, as presented in the Company’s statement of earnings, represent revenue; and food and beverage products sold which is presented net of discounts, coupons, employee meals and complimentary meals. Revenue is recognized using the five step approach required under the guidelines of ASC 606:</p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">1.</kbd>Identify the contract with the client, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">2.</kbd>Identify the performance obligations in the contract, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">3.</kbd>Determine the transaction price, </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">4.</kbd>Allocate the transaction price to performance obligations in the contract </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:108pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">5.</kbd>Recognize revenues when or as the Company satisfies a performance obligation </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For retail operations, all five steps of revenue recognition occur almost simultaneously. The customer orders food from a menu or store sign, it is given to the customer who then pays for the food order at the cash register. The Company’s store business represented approximately 27.6% and 100% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">For wholesale sales the customer orders wholesale items from a store sign or catalogue, it is given or delivered to the customer who then pays for the items within 7 days of sale. The Company’s store business represented approximately 72.4% and 0% of our revenue for the nine months ended September 30, 2023, and 2022, respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Cash and Cash Equivalents</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On September 30, 2023, and December 31, 2022, the Company’s cash equivalents totaled $195,803 and $124,062 , respectively.</p> 195803 124062 <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Property and equipment</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Property and equipment are stated at cost or fair value. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expenses as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in the results of operations. The estimated useful lives of property and equipment are as follows:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="background-color:#CCEEFF;width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Computers, software, and office equipment</p> </td><td style="background-color:#CCEEFF;width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">1 – 6 years</p> </td></tr> <tr><td style="width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Machinery and equipment</p> </td><td style="width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">3 – 5 years</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Leasehold improvements</p> </td><td style="background-color:#CCEEFF;width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">Lesser of lease term or estimated useful life</p> </td></tr> <tr><td style="width:53.86%" valign="top"><p style="font:10pt Times New Roman;margin:0">Buildings</p> </td><td style="width:46.14%" valign="top"><p style="font:10pt Times New Roman;margin:0">39 years</p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">Equipment that hasn’t been placed into service is not subject to depreciation.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Depreciation expense for the nine months ended September 30, 2023 and 2022 was $232,222 and $23,314, respectively.</p> P1Y P6Y P3Y P5Y P39Y 232222 23314 <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Stock-based Compensation</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the FASB Accounting Standards Codification for disclosure about Stock-Based Compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Leases</i></p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The Company currently follows the guidance in ASC 840 “<i>Leases</i>,” which requires us to evaluate the lease agreements the Company enters into to determine whether they represent operating or capital leases at the inception of the lease.</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), that requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The accounting treatment for finance leases and lessors remains relatively unchanged. The accounting standards update also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB approved an amendment to the new guidance that introduced an alternative modified retrospective transition approach granting companies the option of using the effective date of the new standard as the date of initial application. The Company adopted the standard using the effective date method on December 31, 2022.</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The Company elected the transition package of practical expedients that is permitted by the standard. The package of practical expedients allows the Company to not reassess previous accounting conclusions regarding whether existing arrangements are or contain leases, the classification of existing leases, and the treatment of initial direct costs. The Company did not elect the hindsight transition practical expedient allowed for by the new standard, which allows entities to use hindsight when determining lease term and impairment of ROU assets. Additionally, the Company elected certain other practical expedients offered by the new standard which it will apply to all asset classes, including the option not to separate lease and non-lease components and instead to account for them as a single lease component and the option not to recognize ROU assets and related liabilities that arise from short-term leases (i.e., leases with terms of twelve months or less that do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise).</p> <p style="font:10pt Times New Roman;margin-top:12pt;margin-bottom:0pt;color:#000000;background-color:#FFFFFF;text-align:justify">The standard had a material impact on the balance sheet on the date of adoption, with the most significant impact being the recognition of $900,422 operating lease right-of-use assets and $204,116 operating lease liabilities.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As part of its adoption of the new lease accounting standard, the Company also implemented new internal controls and updated accounting policies and procedures, operational processes and documentation practices to enable the preparation of financial information on adoption. Refer to Note 6: Leases - Accounting Principles and Leases for additional disclosures required as a result of the adoption of this new standard.</p> 900422 204116 <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"><i>Stock Purchase Warrants</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify">The Company has issued warrants to purchase shares of its common stock. Warrants have been accounted for as equity in accordance with FASB ASC 480, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF"><i>Income taxes</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company accounts for income taxes under FASB ASC 740, <i>“Accounting for Income Taxes”</i>. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">enactment date. FASB ASC 740-10-05, <i>“Accounting for Uncertainty in Income Taxes”</i> prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions on a quarterly basis to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</p> <p style="font:10pt Times New Roman;margin:0;color:#333333;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><span style="color:#333333;background-color:#FFFFFF">On Dec. 18, 2019, the Financial Accounting Standards Board (FASB) released Accounting Standards Update (ASU) 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The FASB has stated that the ASU is being issued as part of its Simplification Initiative, which is meant to reduce complexity in accounting standards by improving certain areas of generally accepted accounting principles (GAAP) without compromising information provided to users of condensed consolidated financial statements. </span><span style="background-color:#FFFFFF">The Company adopted this guidance on January 1, 2021, which had no impact on the Company’s condensed consolidated financial statements.</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"><i>Net Loss per Share</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, "Earnings per Share." Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and diluted common share equivalents outstanding.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:12pt Times New Roman;margin:0;text-align:justify"><span style="font-size:9pt;border-bottom:1px solid #000000"><i>Discontinued Operations</i></span></p> <p style="font:9pt Times New Roman;margin:0"> </p> <p style="font:12pt Times New Roman;margin:0;text-align:justify"><span style="font-size:9pt">The operations of the Company’s former Winn Sushi Division has been presented as discontinued operations. Unless otherwise noted, amounts and disclosures throughout these Notes to Condensed Consolidated Financial Statements relate solely to continuing operations and exclude all discontinued operations. See Note 4. for additional information on discontinued operations.</span></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Recent Accounting Pronouncements</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i>, which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, <i>Codification Improvements</i>, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, <i>Codification Improvements to Topic 842, Leases </i>in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases <i>(Topic 842) Targeted Improvements,</i> which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard. On November 15, 2019, the FASB has issued ASU 2019-10, which amends the effective dates for three major accounting standards. The ASU defers the effective dates for the credit losses, derivatives, and lease standards for certain companies.   The Company adopted ASC 842 on December 31, 2022.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 3 – PROPERTY, PLANT, AND EQUIPMENT</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The following table sets forth the components of the Company’s property and equipment on September 30, 2023, and December 31, 2022:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="10" style="width:36.92%;border-bottom:1pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>September 30, 2023</b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="12" style="width:38.5%;border-bottom:1pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>December 31, 2022</b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td></tr> <tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.32%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Gross Carrying Amount</b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:11.36%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Accumulated Depreciation</b></p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="3" style="width:12.1%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Net Book Value</b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.12%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Gross Carrying Amount</b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.9%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Accumulated Depreciation</b></p> </td><td style="width:2.76%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:12.08%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Net Book Value</b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:21.34%;padding-top:0.75pt;padding-left:10pt;padding-bottom:0.75pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-indent:-10pt">Computers, software, property, and equipment</p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.14%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">3,761,670</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.42%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.94%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:1pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">(469,579)</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.86%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:11.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,292,091</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.92%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">4,060,518</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.62%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.28%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">(242,382)</kbd> </p> </td><td style="background-color:#CCEEFF;width:2.76%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:11.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,818,136</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> <tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0">Land</p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.14%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.18%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">150,000</kbd> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.42%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.94%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">- </kbd> </p> </td><td style="width:0.86%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.74%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="width:11.34%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">150,000</kbd> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.92%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.18%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">199,000</kbd> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.62%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.28%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">- </kbd> </p> </td><td style="width:2.76%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.74%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:11.34%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">199,000</kbd> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:21.34%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0">Total fixed assets</p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.14%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">3,911,670</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:1pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">(469,579)</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:11.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,442,091</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">4,259,518</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.62%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.28%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">(242,382)</kbd> </p> </td><td style="background-color:#CCEEFF;width:2.76%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:11.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">4,017,136</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">On September 21, 2021 the Company entered into an Exchange Agreement with Yoshi Properties, LLC, an Ohio limited liability company and its sole members, Peter and Vila Thawnghmung who are both officers and directors of the Company, and related parties. Under the terms of the Exchange Agreement the Company purchased ownership of all of the membership interests (100%) in Yoshi Properties, comprised solely of two properties and the related mortgages for consideration of 1,000,000 shares of the Company’s common stock. No other assets or liabilities were included in the purchase price.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The fair market value of the properties acquired from Yoshi Properties, LLC was estimated to be equivalent to the mortgages assumed, or approximately $695,000. The 1,000,000 shares issued to Yoshi Properties was recorded at a value of $0.50 per share which was equivalent to the price of $0.50 per share paid by investors in the Company’s private placement offering of common stock at that time. As a result the Company recorded $500,000 in stock-based compensation expenses on its Statements of Operations for the year ended December 31, 2021.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="10" style="width:36.92%;border-bottom:1pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>September 30, 2023</b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="12" style="width:38.5%;border-bottom:1pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>December 31, 2022</b></p> </td><td colspan="2" style="width:0.82%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td></tr> <tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.32%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Gross Carrying Amount</b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:11.36%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Accumulated Depreciation</b></p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="3" style="width:12.1%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Net Book Value</b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.12%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Gross Carrying Amount</b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:10.9%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Accumulated Depreciation</b></p> </td><td style="width:2.76%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td><td colspan="2" style="width:12.08%" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Net Book Value</b></p> </td><td colspan="2" style="width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><b> </b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:21.34%;padding-top:0.75pt;padding-left:10pt;padding-bottom:0.75pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0;text-indent:-10pt">Computers, software, property, and equipment</p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.14%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">3,761,670</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.42%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.94%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:1pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">(469,579)</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.86%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:11.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,292,091</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.92%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">4,060,518</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.62%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.28%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">(242,382)</kbd> </p> </td><td style="background-color:#CCEEFF;width:2.76%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:11.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,818,136</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> <tr><td style="width:21.34%" valign="bottom"><p style="font:9pt Times New Roman;margin:0">Land</p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.14%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.18%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">150,000</kbd> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.42%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.94%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">- </kbd> </p> </td><td style="width:0.86%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.74%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="width:11.34%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">150,000</kbd> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.92%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.18%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">199,000</kbd> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:1.62%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:9.28%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">- </kbd> </p> </td><td style="width:2.76%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:0.74%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:11.34%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">199,000</kbd> </p> </td><td colspan="2" style="width:0.8%" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:21.34%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0">Total fixed assets</p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.14%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">3,911,670</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:1pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:45pt">(469,579)</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:11.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">3,442,091</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.18%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">4,259,518</kbd> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:1.62%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:9.28%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:0pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:43pt">(242,382)</kbd> </p> </td><td style="background-color:#CCEEFF;width:2.76%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.74%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:11.34%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:4pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:49pt">4,017,136</kbd> </p> </td><td colspan="2" style="background-color:#CCEEFF;width:0.8%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td></tr> </table> 3761670 469579 3292091 4060518 242382 3818136 150000 0 150000 199000 0 199000 3911670 469579 3442091 4259518 242382 4017136 <p style="font:12pt Times New Roman;margin:0;text-align:justify"><span style="font-size:9pt"><b>NOTE 4 – DISCONTINUED OPERATIONS</b></span></p> <p style="font:9pt Times New Roman;margin:0"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana. As a result, Win Sushi became a discontinued operation.</p> <p style="font:10pt Times New Roman;margin:0"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">The components of the loss from discontinued operations for the three and nine months ended September 30, 2023, and 2022 in the statement of operations consisted of the following:</p> <p style="font:10pt Times New Roman;margin:0"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;text-align:center"> </p> </td><td colspan="3" style="width:29.5%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"><b>Three Months Ended </b><br/><b>September 30,</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"> </p> </td><td colspan="3" style="width:29.48%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"><b>Nine Months Ended </b><br/><b>September 30,</b></p> </td></tr> <tr><td style="width:39.82%" valign="top"></td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.9pt;margin-right:18.95pt;text-align:center"><b>2023</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.9pt;margin-right:18.95pt;text-align:center"><b>2022</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.95pt;margin-right:18.95pt;text-align:center"><b>2023</b></p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.95pt;margin-right:18.95pt;text-align:center"><b>2022</b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Revenue</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">746,462</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">866,247 </kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">2,069,135</kbd> </p> </td></tr> <tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Cost of goods sold</p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">715,906</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">798,911 </kbd> </p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">1,834,625</kbd> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Gross Profit</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">30,556</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">67,336 </kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">234,510</kbd> </p> </td></tr> <tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Operating expenses</p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">21,509</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">174,516 </kbd> </p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">25,572</kbd> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Discontinued operations, net of tax</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">9,047</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">(107,180)</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">208,938</kbd> </p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;text-align:center"> </p> </td><td colspan="3" style="width:29.5%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"><b>Three Months Ended </b><br/><b>September 30,</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"> </p> </td><td colspan="3" style="width:29.48%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:2.5pt;text-align:center"><b>Nine Months Ended </b><br/><b>September 30,</b></p> </td></tr> <tr><td style="width:39.82%" valign="top"></td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.9pt;margin-right:18.95pt;text-align:center"><b>2023</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.9pt;margin-right:18.95pt;text-align:center"><b>2022</b></p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.95pt;margin-right:18.95pt;text-align:center"><b>2023</b></p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:18.95pt;margin-right:18.95pt;text-align:center"><b>2022</b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Revenue</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">746,462</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">866,247 </kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">2,069,135</kbd> </p> </td></tr> <tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Cost of goods sold</p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">715,906</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">798,911 </kbd> </p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">1,834,625</kbd> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Gross Profit</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">30,556</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">67,336 </kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">234,510</kbd> </p> </td></tr> <tr><td style="width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Operating expenses</p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">21,509</kbd> </p> </td><td style="width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">174,516 </kbd> </p> </td><td style="width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="width:14.16%;border-bottom:0.5pt solid #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">25,572</kbd> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:39.82%" valign="top"><p style="font:9pt Times New Roman;margin:0;margin-left:4.5pt">Discontinued operations, net of tax</p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">-</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">9,047</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.18%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">(107,180)</kbd> </p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="top"><p style="font:9pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:14.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:9pt Times New Roman;margin:0"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:7pt">$</kbd><kbd style="position:absolute;text-align:right;font:9pt Times New Roman;width:59pt">208,938</kbd> </p> </td></tr> </table> 0 746462 866247 2069135 0 715906 798911 1834625 0 30556 67336 234510 0 21509 174516 25572 0 9047 -107180 208938 <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><b>NOTE 5 – MORTGAGES PAYABLE</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The balance in mortgages payable was $1,549,713 and $1,728,883 as of September 30, 2023, and December 31, 2022, respectively. The mortgage balance as of September 30, 2023, is comprised of:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Mortgage Loans: CNB Bank- OH Store = $ 270,466 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Mortgage Loans: Old National Bank- LA Store/Fac = $ 525,380 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Mortgage Loans: Old National Loan- IN Factory = $ 260,240 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Mortgage Loans: Old National – 7K farms - Mtg = $ 493,627 </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Interest expense on these mortgages were $66,522 and $34,024, for the nine months ended September 30, 2023, and September 30, 2022, respectively. The interest expense balance as of September 30, 2023, is comprised of:</p> <p style="font:10pt Symbol;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Interest Expense: OH Store- CNB Bank = $ 15,647 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:72pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">o</kbd><span style="color:#333333;background-color:#FFFFFF">Interest Rate: 7.34%</span> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Interest Expense: LA Store/Factory- Old National = $ 16,239 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:72pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">o</kbd><span style="color:#333333;background-color:#FFFFFF">Interest Rate: 4%</span> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Interest Expense: IN Factory- Old National = $ 8,046 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:72pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt">o</kbd><span style="color:#333333;background-color:#FFFFFF">Interest Rate: 4%</span> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Interest Expense: 7K Farms RE - Old National = $ 26,590 </p> <p style="font:10pt Times New Roman;margin:0;margin-left:72pt;color:#333333;text-align:justify"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-18pt"><span style="color:#000000">o</span></kbd><span style="background-color:#FFFFFF">Interest Rate: 6.5%</span> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">On September 30, 2023, the aggregate maturities of notes payable for the next five years and thereafter are as follows:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse"><tr><td style="background-color:#CCEEFF;width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2022</p> </td><td style="background-color:#CCEEFF;width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2023</p> </td><td style="width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$ </p> </td><td style="width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2024</p> </td><td style="background-color:#CCEEFF;width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2025</p> </td><td style="width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2026 and thereafter</p> </td><td style="background-color:#CCEEFF;width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,549,713 </p> </td></tr> <tr><td style="width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">Total</p> </td><td style="width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="width:130.5pt;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,549,713 </p> </td></tr> </table> 1549713 1728883 270466 525380 260240 493627 15647 16239 8046 26590 <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse"><tr><td style="background-color:#CCEEFF;width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2022</p> </td><td style="background-color:#CCEEFF;width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2023</p> </td><td style="width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$ </p> </td><td style="width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:315pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2024</p> </td><td style="background-color:#CCEEFF;width:9pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2025</p> </td><td style="width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="width:130.5pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right"> -</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">2026 and thereafter</p> </td><td style="background-color:#CCEEFF;width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:13.5pt;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="background-color:#CCEEFF;width:130.5pt;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,549,713 </p> </td></tr> <tr><td style="width:315pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0">Total</p> </td><td style="width:9pt;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:2.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="width:13.5pt;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0">$</p> </td><td style="width:130.5pt;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,549,713 </p> </td></tr> </table> 0 0 0 0 1549713 1549713 <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 6 – RELATED PARTY TRANSACTIONS</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Peter Thawnghmung, the Company’s Chairman and CEO is the spouse of Vila Thawnghmung, who is a director of the Company. The Company has 4 directors, therefore, Peter and Vila Thawnghmung, two of those directors can control all Company activity. Peter and Vila Thawnghmung have personally guaranteed all of the mortgages on the real properties owned by the Company and its subsidiaries as well as the Line of Credit. Arianna Phrakornkham, their daughter, is the controller of the Company.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">In 2021 Peter and Vila Thawnghmung received 1,048,000 common shares for services performed. These shares were valued at $524,000. Related parties to Peter and Vila Thawnghmung received 120,000 common shares for services valued at $60,000.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">In 2022 Peter and Vila Thawnghmung received 9,051,000 common shares for services performed. These shares were valued at $4,525,500. Arianna Phrakornkham received 1,000,000 shares valued at $500,000 for services. Related parties to Peter and Vila Thawnghmung received 1,127,000 common shares valued at $63,500.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000;text-align:justify">During the nine months ended September 30, 2023, Peter and Vila Thawnghmung received 68,000 shares for service performed. These share were valued at $34,000. During this period, Rome Thalop, who was appointed a director on March 23, 2023, received 16,000 shares valued at $8,000 for his ongoing services as a director.</p> 1048000 524000 120000 60000 9051000 4525500 1000000 500000 1127000 63500 68000 34000 16000 8000 <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 7 – LINE OF CREDIT</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As of September 30, 2023, the Company has one line of credit with Old National Bank. The interest rate is 8.75% with a credit limit of $500,00 and a loan term of 24 months. The loan originated on 10/31/2022 and expires on 10/31/2024. The line of credit is collateralized by 7K Farms and was personally guaranteed by Peter and Vila Thawnghmung. The balance of the line of credit was $484,900 and $61,490 as of September 30, 2023 and September 30, 2022, respectively.</p> the Company has one line of credit with Old National Bank. The interest rate is 8.75% with a credit limit of $500,00 and a loan term of 24 months. The loan originated on 10/31/2022 and expires on 10/31/2024. The line of credit is collateralized by 7K Farms and was personally guaranteed by Peter and Vila Thawnghmung. The balance of the line of credit was $484,900 and $61,490 as of September 30, 2023 and September 30, 2022, respectively <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 8 – LEASES</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">As of September 30, 2023, the Company had signed 6 long-term leases:</p> <p style="font:10pt Symbol;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Flushing, New York: The Company entered into a lease for $7,500/month with a lease term of 5 years (11/25/2020 – 11/15/2025). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Columbus, Ohio: The Company entered into a lease for $3,370.83/month with a lease term of 7 years (6/4/2021 – 3/31/2028). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Indianapolis, Indiana: The Company entered into a lease for $3,065.75/month with a lease term of 5 years (5/1/2021 – 4/30/2026). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Indianapolis, Indiana: The Company entered into a lease for $4,200/month with a lease term of 6 years (6/1/2022 – 5/31/2028). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Indianapolis, Indiana: The Company entered into a lease for $4,911.83/month with a lease term of 5 years (5/1/2023 – 10/31/2028). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt">·</kbd>Columbus, Ohio: The Company entered into a lease for $3,798/month with a lease term of 5.6 years (9/1/2023 – 4/31/2029). </p> <p style="font:10pt Times New Roman;margin:0;margin-left:90pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Accounting Principles</i></p> <p style="font:12pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Under ASC 842, the determination of whether an arrangement is a lease is made at the lease’s inception and a contract is (or contains) a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is defined under the standard as having both the right to obtain substantially all of the economic benefits from use of the asset and the right to direct the use of the asset. Management only reassesses its determination if the terms and conditions of the contract are changed. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our balance sheets.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when it is readily determinable. Since most of the Company’s leases do not provide an implicit rate, to determine the present value of lease payments, management uses the Company’s incremental borrowing rate based on the information available at lease commencement. Operating lease ROU assets also include any lease payments made and exclude any lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option, with renewal options that can extend the lease from three to five years. Leases with an initial term of 12 months or less are not recorded on the balance sheet.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company has lease agreements with lease and non-lease components, for which it has made an accounting policy election to account for these as a single lease component.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>Leases</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company leases retail spaces under operating lease agreements that have term lengths of five to seven years and that have renewal options that range from three to five years. The Company pays certain variable lease costs such as real estate taxes, insurance, and common area maintenance charges. The Company accounts for lease and non-lease components as a single lease component.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:78.2%" valign="bottom"><p style="font:10pt Times New Roman;margin:0"><b>Lease Cost</b></p> </td><td style="width:3.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.1%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"> </p> </td><td style="width:1.04%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="width:78.2%" valign="middle"></td><td style="width:3.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.1%" valign="middle"></td><td style="width:1.04%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Operating lease cost</p> </td><td style="background-color:#CCEEFF;width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="background-color:#CCEEFF;width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$ </p> </td><td style="background-color:#CCEEFF;width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">220,622</p> </td><td style="background-color:#CCEEFF;width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Short-term lease cost</p> </td><td style="width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,854</p> </td><td style="width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Variable lease cost</p> </td><td style="background-color:#CCEEFF;width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">27,166</p> </td><td style="background-color:#CCEEFF;width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Total lease cost</p> </td><td style="width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:2.32%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="width:14.78%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">251,642</p> </td><td style="width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The weighted average remaining lease term for operating leases is 3.73 years and the weighted average discount rate for operating leases is 4%.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Maturities of lease liabilities as of September 30, 2023, were as follows:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:80.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:1.08%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.66%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"><b>Operating</b></p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td colspan="2" style="width:17.66%;border-bottom:0.75pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"><b>Leases</b></p> </td><td style="width:0.58%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2023</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000" valign="bottom"></td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2024</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">212,833</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2025</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">208,660</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2026</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">103,114</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2027</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">95,650</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Thereafter</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">33,112</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;margin-left:13.7pt;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">809,679</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Less imputed interest</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">70,124</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;margin-left:13.7pt;color:#000000">Total</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">739,555</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> </table> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">Operating cash flows from operating leases for the year ended December 31, 2022, was $197,187, and lease assets were obtained in exchange for operating lease liabilities for the year ended December 31, 2022, of $693,230.</p> 7500 3370 3065 4200 4911 3798 <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:78.2%" valign="bottom"><p style="font:10pt Times New Roman;margin:0"><b>Lease Cost</b></p> </td><td style="width:3.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.1%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"> </p> </td><td style="width:1.04%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="width:78.2%" valign="middle"></td><td style="width:3.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.1%" valign="middle"></td><td style="width:1.04%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="background-color:#CCEEFF;width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Operating lease cost</p> </td><td style="background-color:#CCEEFF;width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="background-color:#CCEEFF;width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$ </p> </td><td style="background-color:#CCEEFF;width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">220,622</p> </td><td style="background-color:#CCEEFF;width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Short-term lease cost</p> </td><td style="width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">3,854</p> </td><td style="width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Variable lease cost</p> </td><td style="background-color:#CCEEFF;width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:2.32%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:14.78%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">27,166</p> </td><td style="background-color:#CCEEFF;width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:78.2%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Total lease cost</p> </td><td style="width:3.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:2.32%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="width:14.78%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">251,642</p> </td><td style="width:1.04%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> </table> 220622 3854 27166 251642 <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:80.68%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:1.08%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td colspan="2" style="width:17.66%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"><b>Operating</b></p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td colspan="2" style="width:17.66%;border-bottom:0.75pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"><b>Leases</b></p> </td><td style="width:0.58%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2023</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000" valign="bottom"></td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2024</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">212,833</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2025</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">208,660</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2026</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right"> </p> </td><td style="width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">103,114</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">2027</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">95,650</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Thereafter</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">33,112</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;margin-left:13.7pt;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">809,679</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000">Less imputed interest</p> </td><td style="width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="width:1.16%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td><td style="width:16.5%;border-bottom:0.75pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">70,124</p> </td><td style="width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> <tr><td style="background-color:#CCEEFF;width:80.68%" valign="middle"><p style="font:10pt Times New Roman;margin:0;margin-left:13.7pt;color:#000000">Total</p> </td><td style="background-color:#CCEEFF;width:1.08%" valign="middle"><p style="font:10pt Times New Roman;margin:0;color:#000000"><b> </b></p> </td><td style="background-color:#CCEEFF;width:1.16%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000">$</p> </td><td style="background-color:#CCEEFF;width:16.5%;border-top:0.75pt solid #000000;border-bottom:3px double #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:right">739,555</p> </td><td style="background-color:#CCEEFF;width:0.58%" valign="bottom"><p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> </td></tr> </table> 212833 208660 103114 95650 33112 809679 70124 739555 197187 693230 <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 9 – EQUITY</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">The Company has authorized 100,000,000 shares of par value of $0.0001 common stock. As of September 30, 2023, and December 31, 2022, the Company had 77,226,355 and 70,590,898 common shares issued and outstanding, respectively.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>September 30, 2023 Activity</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">During the nine months ended September 30, 2023, the Company had the following common stock transactions:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Issuance of 6,375,357 shares for services valued at $3,187679. </p> <p style="font:10pt Symbol;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Issuance of 260,000 shares in private placements valued at $130,000. </p> <p style="font:10pt Times New Roman;margin:0;text-indent:-18pt;margin-left:36pt;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><i>December 31, 2022 Activity</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">During the year ended December 31, 2022, the Company had the following common stock transactions:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Issuance of 2,773,900 shares in private placements valued at $1,534,999. </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Issuance of 15,584,000 shares for services valued at $7,792,000. </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:36pt;color:#000000;text-align:justify"><kbd style="position:absolute;font:10pt Symbol;margin-left:-18pt"><span style="font-family:Symbol">·</span></kbd>Issuance of 1,000,000 shares for the purchase of 7K Farms valued at $500,000. </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">Warrants</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As of September 30, 2023, the Company had 6,059,998 warrants outstanding, all with a strike price of $1.25. The warrants have a two-year term and expire at varying times between September 30, 2023 and June 13, 2025.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000">A summary of the status of the outstanding stock warrants is presented below:</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:23.5%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Exercise Price</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:22.12%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Number Outstanding</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">9/30/2023</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:29.64%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Weighted Average</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">Remaining Contractual Life</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:19.6%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Weighted Average</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">Exercise Price</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:23.5%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1.25</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:22.12%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">6,059,998</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:29.64%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.39 years</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:19.6%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1.25</p> </td></tr> </table> 100000000 0.0001 77226355 70590898 6375357 3187679 260000 130000 2773900 1534999 15584000 7792000 1000000 500000 6059998 <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <table style="border-collapse:collapse;width:100%"><tr><td style="width:23.5%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Exercise Price</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:22.12%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Number Outstanding</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">9/30/2023</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:29.64%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Weighted Average</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">Remaining Contractual Life</p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center"> </p> </td><td style="width:19.6%;border-bottom:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">Weighted Average</p> <p style="font:10pt Times New Roman;margin:0;text-align:center">Exercise Price</p> </td></tr> <tr><td style="background-color:#CCEEFF;width:23.5%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1.25</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:22.12%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">6,059,998</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:29.64%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">0.39 years</p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:0.86%;padding-top:0.75pt;padding-left:0.75pt;padding-bottom:1.5pt;padding-right:0.75pt" valign="bottom"><p style="font:10pt Times New Roman;margin:0"> </p> </td><td style="background-color:#CCEEFF;width:19.6%;border-top:0.5pt solid #000000" valign="bottom"><p style="font:10pt Times New Roman;margin:0;text-align:center">$1.25</p> </td></tr> </table> 6059998 P0Y4M20D 1.25 <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><b>NOTE 10 – COMMITMENTS AND CONTINGENCIES</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify"><i>Legal Proceedings</i></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;background-color:#FFFFFF;text-align:justify">On April 20, 2021, the Company entered into a purchase agreement with Epitome of Agape, LLC d/b/a Win’s Sushi (“Epitome”) a vendor who supplies sushi products to 19 grocery stores in Louisiana for the Company’s subsidiary, Yoshi Inc. On or around May 15, 2023, the Company believes that Epitome materially breached that purchase agreement causing the Company to prospectively lose all of its revenue from its sushi business at all 19 stores in Louisiana.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"><b>NOTE 11 – SUBSEQUENT EVENTS</b></p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:center"> </p> <p style="font:10pt Times New Roman;margin:0;color:#000000;text-align:justify">As of September 30, 2023, the Company had 77,226,355 shares of its common stock issued and outstanding. Subsequent to September 30, 2023, the Company had 77,717,721 shares of its common stock issued and outstanding. From October 1, 2023 – March 5, 2024, an additional 491,366 shares were issued, 431,366 shares were for services.</p>